Qiagen NV (QGEN)

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakMay 28, 2026 4:05 PM
Business Wire Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater surveillance and other environmental monitoring settings. They were developed using publicly available genomic sequence information released during the outbreak response and are part of QIAGEN’s broader Sample to Insight portfolio supporting infectious disease research workflows. The assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by QIAGEN. The assays are intended for research use only and are not intended for diagnostic procedures. The availability of these assays underscores the role of adaptable molecular technologies in supporting public health research infrastructure. As genomic information from emerging infectious disease events becomes available, laboratories need flexible tools that can be evaluated and incorporated into existing research, surveillance and environmental monitoring workflows. QIAGEN’s current portfolio supporting this infectious disease outbreak includes: Research-use-only digital PCR assays targeting the NP and VP35 regions of Bundibugyo ebolavirus are available through QIAGEN’s custom assay workflow on a make-to-order basis. QIAseq sequencing panels are available from stock for fast delivery. Existing sample preparation and molecular workflow kits are available from stock to support nucleic acid processing for downstream digital PCR and next-generation sequencing workflows to support wastewater surveillance and molecular research applications. “Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QIAGEN is committed to supporting customers around the world with adaptable molecular technologies that help strengthen infectious disease research and surveillance capacity. Our goal remains clear: no country should be left behind when new threats emerge.” The QIAcuity digital PCR system supports sensitive nucleic acid detection and quantification across a range of research applications, including infectious disease research and environmental surveillance. Combined with QIAGEN’s broader Sample to Insight portfolio, the platform enables laboratories to rapidly adapt existing workflows as new pathogen targets emerge. Further information about QIAcuity digital PCR solutions and custom assay workflows is available through local QIAGEN representatives or customer care team. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com. Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Infectious Diseases View source version on businesswire.com: https://www.businesswire.com/news/home/20260528851547/en/ QIAGEN contacts: Public Relations
e-mail: pr@QIAGEN.com Investor Relations
e-mail: ir@QIAGEN.com Original: QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsMay 20, 2026 4:05 PM
Business Wire New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface. “Researchers today are navigating growing scientific complexity, increasing volumes of data and expanding workflow choices,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIA Agent is designed to simplify how researchers interact with scientific information, workflow guidance and operational support through a single AI-powered experience. By embedding conversational AI into our digital ecosystem, we aim to help customers move faster from questions to decisions across Sample to Insight workflows.” As laboratories generate increasing amounts of data and workflows become more complex, researchers are seeking more intuitive ways to access scientific expertise, technical guidance and operational support. Conversational AI is emerging as a new interface layer for scientific workflows, helping reduce friction across research, purchasing and laboratory operations. QIA Agent addresses these challenges by connecting QIAGEN’s product information, protocols, technical documentation, ordering tools and support resources through a natural-language interface. It is accessible with or without login, allowing users to engage immediately while offering a more personalized experience when signed in. Logged-in users can access individual pricing, order history and account-specific information, making interactions more relevant and efficient. With more than 260,000 users already registered on “My QIAGEN” at www.qiagen.com, the platform builds on an established digital customer base. Key features and benefits include: Natural-language scientific guidance: Researchers can interact with QIA Agent through a conversational interface and receive guidance linked to relevant QIAGEN products, protocols, technical information and recommended next steps. Connected product and workflow intelligence: QIA Agent combines product information, protocols, technical documentation and support resources to support decision-making for experiment planning and product selection. Integration with QIAGEN digital services: The platform connects researchers with existing QIAGEN tools, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center to create a seamless interface from experiment planning through post-purchase support. Ordering and support access in one place: Researchers can check product availability, track orders and access relevant support information without moving across multiple systems. Improved laboratory efficiency: By simplifying access to scientific information, digital tools and operational support, QIA Agent is designed to help laboratories save time, improve productivity through faster and more informed decisions. QIA Agent is now publicly accessible via www.qiagen.com to all QIAGEN customers worldwide. It is currently intended for research use and is not designed for diagnostic applications. The launch of QIA Agent forms part of QIAGEN’s broader efforts to apply AI and digital technologies across its customer-facing ecosystem. By embedding AI-enabled assistance into laboratory workflows, QIAGEN aims to make scientific information, product selection and operational support easier to access for researchers worldwide. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com. Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate View source version on businesswire.com: https://www.businesswire.com/news/home/20260520732949/en/ QIAGEN contacts: Public Relations
e-mail: pr@QIAGEN.com Investor Relations
e-mail: ir@QIAGEN.com Original: QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIAMay 19, 2026 4:05 PM
Business Wire Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery. The integration is designed to help pharmaceutical and biotechnology researchers better understand disease biology, identify promising therapeutic targets and uncover biomarkers that can support faster and more effective development of new medicines. Drug discovery depends on connecting large amounts of complex biological information, including genes, diseases, pathways, compounds and clinical evidence. For many research teams, the challenge is finding the most relevant connections amid increasing amounts of data to understand why they matter and assess whether an AI-generated insight is supported by credible biology. QIAGEN and NVIDIA are working to address this challenge through graph-based AI. This approach applies retrieval and reasoning techniques over biomedical knowledge graphs, allowing researchers to explore evidence across biological systems and supporting a path toward agentic, multi-step workflows for drug discovery. “QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation.” The collaboration is designed to support practical applications across the drug discovery lifecycle, including target identification and validation, drug repurposing, biomarker discovery, pathway analysis and hypothesis generation from multi-omics data. By combining curated biomedical knowledge, graph-based AI and accelerated computing, QIAGEN aims to help research teams move from complex data to better-informed discovery decisions. Initial pilot programs will be made available to select pharmaceutical and biotechnology partners, with broader availability of these new solutions expected following validation. QIAGEN Digital Insights is developing a range of new AI-enhanced solutions designed to help life sciences organizations extract more value from complex biological, clinical and molecular data. These solutions build on more than 25 years of curated biomedical knowledge, including knowledge bases used by more than 150,000 scientists worldwide and supported by more than 70,000 scientific publications. By organizing evidence across genes, diseases, pathways, compounds, clinical insights and more than 30,000 diseases, QIAGEN Digital Insights provides the scientific context needed to help researchers assess whether AI-generated insights are biologically credible, novel and relevant to drug discovery. QIAGEN's Discovery Platform integrates curated information across genes, diseases, pathways, compounds and clinical insights. To support AI-driven querying across this knowledge graph, the platform is designed to incorporate graph-based retrieval AI drawing on frameworks such as PyTorch Geometric and GPU accelerated GraphRAG systems, with delivery through the NVIDIA BioNeMo platform. This will enable researchers to ask natural language questions across biomedical knowledge graphs while retaining a clear link to structured scientific evidence. To learn more about the pilot program or explore how the QIAGEN Discovery Platform can support your drug discovery workflows, visit https://digitalinsights.qiagen.com/qiagen-discovery-platform or contact Matthew.Mansson@qiagen.com. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com. Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Bioinformatics View source version on businesswire.com: https://www.businesswire.com/news/home/20260519902250/en/ Public Relations
e-mail: pr@QIAGEN.com Investor Relations
e-mail: ir@QIAGEN.com Original: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingMay 12, 2026 2:00 AM
Business Wire Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been appointed; Roland Sackers to stand for re-election to Managing Board QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders. The Annual General Meeting, to be held on June 24, 2026, in Venlo, the Netherlands, will include proposals to elect Robert McMahon as a new member of the Supervisory Board, approve a 40% increase in the annual cash dividend and authorize additional shareholder returns through a synthetic share repurchase of up to the currently allowed maximum of $200 million as well as further open-market share repurchases. These proposals come as QIAGEN continues a significant renewal of its Supervisory Board. Following the Annual General Meeting, seven of the eight proposed Supervisory Board members will have joined since 2021, while maintaining continuity and institutional knowledge through longer-tenured members and experienced Board and committee leadership. Following the Annual General Meeting, the Supervisory Board would continue to be composed of eight members: Stephen H. Rusckowski (Chair), Dr. Toralf Haag, Bert van Meurs, Robert McMahon, Eva van Pelt, Dr. Eva Pisa, Mark P. Stevenson and Elizabeth E. Tallett. “We are deeply grateful to Metin Colpan for his extraordinary contributions to QIAGEN as co-founder, first Chief Executive Officer and long-serving member of the Supervisory Board,” said Stephen H. Rusckowski, Chair of the Supervisory Board. “These proposals outlined for the Annual General Meeting continue the renewal of our Supervisory Board and reaffirm our commitment to best corporate governance practices, strong Board oversight and long-term value creation for shareholders and other stakeholders.” Dr. Metin Colpan to be appointed Honorary Chairman of the Supervisory Board Dr. Colpan has decided to conclude his service on the Supervisory Board at the Annual General Meeting and will not stand for re-election. In recognition of his contributions to QIAGEN, the Supervisory Board intends to appoint him as Honorary Chairman following the meeting. Dr. Colpan played a defining role in QIAGEN’s creation and development, helping establish its scientific foundation, entrepreneurial culture and long-term strategic direction. A co-founder of QIAGEN, he served as Chief Executive Officer from 1985 to 2003 and helped build the company from a university-linked start-up in Düsseldorf into a global leader in Sample to Insight solutions. Dr. Colpan’s pioneering scientific work in nucleic acid separation and purification helped shape technologies that became important QIAGEN products, and have since been widely adopted in molecular biology labs across the world. These innovations have enabled faster, more reliable and more efficient isolation and analysis of DNA and RNA, supporting advances across the Life Sciences and clinical diagnostics. Since 2004, Dr. Colpan has continued to contribute to QIAGEN’s strategic and scientific direction as a member of the Supervisory Board, including as Chair of the Science & Technology Committee since 2014. His contributions have also received external recognition, including his selection as a finalist for the European Patent Office’s 2021 European Inventor Award in the lifetime achievement category. Beyond his scientific and entrepreneurial contributions, Dr. Colpan has been closely associated with QIAGEN’s people-centered culture, emphasizing the importance of translating scientific innovation into lasting impact for customers, patients and society. “I am deeply grateful to the many QIAGENers whose commitment, expertise and passion have shaped QIAGEN’s development and helped support the genomic revolution,” said Dr. Colpan. “Their work has helped turn scientific ideas into trusted products that support research, diagnostics and better healthcare decisions around the world. It is a privilege to be part of this journey, and I look forward to remaining connected as QIAGEN continues to advance science and improve healthcare.” Robert McMahon proposed for election to Supervisory Board Robert McMahon, the Chief Financial Officer of West Pharmaceutical Services, Inc., has been proposed for election to the Supervisory Board. Prior to this role, he served as Chief Financial Officer of Agilent Technologies Inc. from 2018 to 2025, and as Chief Financial Officer of Hologic, Inc. from 2014 to 2018. Earlier in his career, Mr. McMahon spent 20 years with Johnson & Johnson in executive finance roles of increasing responsibility. He also serves on the Board of Directors of OraSure Technologies, Inc. Mr. McMahon earned a Master of Business Administration from the University of Central Florida and a bachelor’s degree in Finance from the University of Florida. “We are pleased to propose Robert McMahon for election to QIAGEN’s Supervisory Board,” said Mr. Rusckowski. “He would further strengthen the profile of the Board with deep experience in global healthcare, Life Sciences and public company finance. His financial acumen and track record in the capital markets will be valuable as QIAGEN continues to focus on execution and disciplined capital allocation to the highest return opportunities.” Proposed annual dividend QIAGEN is proposing a 40% increase in its annual cash dividend to $0.35 per ordinary share, compared with the initial annual dividend of $0.25 approved by shareholders in 2025. QIAGEN introduced its first annual dividend in 2025 as an additional way to return capital to shareholders while preserving flexibility to reinvest in long-term growth. The proposed 2026 dividend reflects a disciplined capital allocation approach focused on the highest return opportunities that also includes organic investments, particularly in R&D and commercialization initiatives, as well as targeted M&A opportunities. The expected dividend timetable for shares listed on both the New York Stock Exchange and Frankfurt Stock Exchange is as follows: ex-date July 7, 2026; record date July 7, 2026; and payment date July 14, 2026. Additional share repurchase authorizations QIAGEN is also seeking shareholder approval for additional share repurchase authorizations as part of its disciplined approach to capital allocation and shareholder returns. These authorizations include authorizations for open-market share repurchases of up to 10% of the Company’s share capital as well as a synthetic share repurchase of up to $200 million. If approved, these authorizations would provide QIAGEN with additional flexibility to return capital to shareholders while continuing to invest in long-term growth opportunities. Managing Board appointments Thierry Bernard, Chief Executive Officer, is also proposed for re-election as a Managing Board member until the appointment of a new CEO. The CEO selection process is progressing well, and a successor is currently expected to join during the second half of 2026. In the meantime, Mr. Bernard will continue to lead QIAGEN with the full support of the Supervisory Board to ensure continuity and focus. Roland Sackers, Chief Financial Officer, also stands for re-election as a Managing Board member. 2026 Annual General Meeting information QIAGEN’s Annual General Meeting will be held on June 24, 2026, at 9:00 a.m. Amsterdam time at Maaspoort, Oude Markt 30, 5911 HH Venlo, the Netherlands. The meeting will also be available via live webcast in listen-only mode. Shareholders will not be able to vote or address the meeting through the webcast and are encouraged to review the materials and vote their shares in advance of the AGM. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com. Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V.
Category: Corporate View source version on businesswire.com: https://www.businesswire.com/news/home/20260511332737/en/ Public Relations
e-mail: pr@QIAGEN.com Investor Relations
e-mail: ir@QIAGEN.com Original: QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

QIAGEN plant die Ernennung von Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, setzt die Neuausrichtung der Aufsichtsratsstruktur fort und schlägt höhere Kapitalrückzahlungen auf der Hauptversammlung 2026 vorMay 12, 2026 2:00 AM
Business Wire Mitgründer und ehemaliger CEO Dr. Metin Colpan soll zum Ehrenvorsitzenden des Aufsichtsrats ernannt werden, nachdem er beschlossen hat, nicht mehr zur Wiederwahl anzutreten Robert McMahon im Rahmen des laufenden Erneuerungsprozesses als neues Aufsichtsratsmitglied nominiert; sieben der acht vorgeschlagenen Mitglieder sind seit 2021 dem Gremium beigetreten Erhöhung der jährlichen Dividende um 40% auf $0,35 je Aktie vorgeschlagen – als Ausdruck des anhaltenden Engagements für höhere Renditen für Aktionärinnen und Aktionäre Zusätzliche Ermächtigungen für Aktienrückkäufe, darunter weitere Aktienrückkäufe am freien Markt sowie ein neuer synthetischer Aktienrückkauf über $200 Mio. Thierry Bernard stellt sich als Vorstandsmitglied zur Wiederwahl, bis ein neuer CEO ernannt wurde; Roland Sackers stellt sich erneut zur Wahl QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Vorschläge für seine Hauptversammlung 2026 bekannt. Dazu gehören die geplante Ernennung von Mitgründer und ehemaligem Chief Executive Officer Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, die weitere Erneuerung des Aufsichtsrats sowie höhere Kapitalrückzahlungen an Aktionärinnen und Aktionäre. Die Hauptversammlung findet am 24. Juni 2026 in Venlo, Niederlande, statt. Auf der Tagesordnung stehen unter anderem Vorschläge zur Wahl von Robert McMahon als neues Mitglied des Aufsichtsrats, zur Genehmigung einer Erhöhung der jährlichen Bardividende um 40% sowie zur Ermächtigung weiterer Kapitalrückzahlungen an Aktionärinnen und Aktionäre durch einen synthetischen Aktienrückkauf von bis zum derzeit genehmigten Höchstbetrag von $200 Mio. sowie weitere Aktienrückkäufe am freien Markt. Diese Vorschläge erfolgen vor dem Hintergrund einer umfassenden Erneuerung des Aufsichtsrats von QIAGEN. Nach der Hauptversammlung werden sieben der acht vorgeschlagenen Mitglieder des Aufsichtsrats dem Gremium seit 2021 beigetreten sein. Gleichzeitig bleiben Kontinuität und institutionelles Wissen durch länger amtierende Mitglieder sowie erfahrene Führungsstrukturen im Aufsichtsrat und seinen Ausschüssen erhalten. Nach der Hauptversammlung würde der Aufsichtsrat weiterhin aus acht Mitgliedern bestehen: Stephen H. Rusckowski als Vorsitzender, Dr. Toralf Haag, Bert van Meurs, Robert McMahon, Eva van Pelt, Dr. Eva Pisa, Mark P. Stevenson und Elizabeth E. Tallett. „Wir sind Metin Colpan zutiefst dankbar für seine außergewöhnlichen Verdienste als Mitgründer, erster Vorstandsvorsitzender und langjähriges Mitglied des Aufsichtsrats von QIAGEN“, sagte Stephen H. Rusckowski, Vorsitzender des Aufsichtsrats. „Die Vorschläge für die Hauptversammlung setzen die Erneuerung unseres Aufsichtsrats konsequent fort und unterstreichen unser Engagement für hohe Corporate-Governance-Praktiken, eine starke Aufsicht durch den Aufsichtsrat und langfristige Wertschöpfung für Aktionärinnen und Aktionäre und andere Stakeholder.“ Dr. Metin Colpan soll zum Ehrenvorsitzenden des Aufsichtsrats ernannt werden Dr. Colpan hat entschieden, seine Tätigkeit im Aufsichtsrat mit der Hauptversammlung zu beenden und nicht erneut zur Wiederwahl anzutreten. In Anerkennung seiner Verdienste um QIAGEN beabsichtigt der Aufsichtsrat, ihn im Anschluss an die Hauptversammlung zum Ehrenvorsitzenden des Aufsichtsrats zu ernennen. Dr. Colpan hat QIAGENs Gründung und Entwicklung maßgeblich geprägt. Er trug entscheidend dazu bei, das wissenschaftliche Fundament, die unternehmerische Kultur und die langfristige strategische Ausrichtung des Unternehmens zu etablieren. Als Mitgründer von QIAGEN war er von 1985 bis 2003 Vorstandsvorsitzender und baute das Unternehmen von einem Universitäts-Start-up in Düsseldorf zu einem weltweit führenden Anbieter von Sample-to-Insight Lösungen auf. Dr. Colpans wegweisende wissenschaftliche Arbeit im Bereich der Trennung und Aufreinigung von Nukleinsäuren trug zur Entwicklung von Technologien bei, aus denen wichtige QIAGEN Produkte hervorgingen und die heute weltweit in molekularbiologischen Laboren eingesetzt werden. Diese Innovationen ermöglichen eine schnellere, zuverlässigere und effizientere Isolierung und Analyse von DNA und RNA und tragen zu Fortschritten in den Life Sciences und der klinischen Diagnostik bei. Seit 2004 prägt Dr. Colpan QIAGENs strategische und wissenschaftliche Ausrichtung weiterhin als Mitglied des Aufsichtsrats, seit 2014 auch als Vorsitzender des Science & Technology Committee. Seine Verdienste wurden auch extern gewürdigt, unter anderem als Finalist beim Europäischen Erfinderpreis 2021 des Europäischen Patentamts in der Kategorie Lebenswerk. Über seine wissenschaftlichen und unternehmerischen Leistungen hinaus prägte Dr. Colpan auch die Unternehmenskultur von QIAGEN, bei der der Mensch im Mittelpunkt steht. Dabei betonte er stets die Bedeutung, wissenschaftliche Innovationen in nachhaltigen Nutzen für Kundinnen und Kunden, Patientinnen und Patienten sowie die Gesellschaft zu übersetzen. „Ich bin den vielen QIAGENern zutiefst dankbar, deren Engagement, Expertise und Leidenschaft QIAGENs Entwicklung geprägt und die genomische Revolution mit vorangetrieben haben“, sagte Dr. Colpan. „Ihre Arbeit hat dazu beigetragen, wissenschaftliche Ideen in verlässliche Lösungen zu übersetzen, die Forschung, Diagnostik und bessere Entscheidungen im Gesundheitswesen weltweit unterstützen. Es ist ein Privileg, Teil dieser Reise zu sein, und ich freue mich darauf, QIAGEN weiterhin verbunden zu bleiben, während das Unternehmen die Wissenschaft voranbringt und die Gesundheitsversorgung weiter verbessert.“ Robert McMahon zur Wahl in den Aufsichtsrat vorgeschlagen Robert McMahon, Finanzvorstand von West Pharmaceutical Services, Inc., wurde zur Wahl in den Aufsichtsrat vorgeschlagen. Zuvor war er von 2018 bis 2025 Finanzvorstand von Agilent Technologies Inc. sowie von 2014 bis 2018 Finanzvorstand von Hologic, Inc. Zu Beginn seiner Karriere war Herr McMahon 20 Jahre lang in Führungspositionen mit zunehmender Verantwortung im Finanzbereich bei Johnson & Johnson tätig. Darüber hinaus ist er Mitglied des Board of Directors von OraSure Technologies, Inc. Herr McMahon hat einen Master of Business Administration der University of Central Florida sowie einen Bachelor-Abschluss in Finance der University of Florida. „Wir freuen uns, Robert McMahon zur Wahl in den Aufsichtsrat von QIAGEN vorzuschlagen“, sagte Herr Rusckowski. „Er würde das Profil des Aufsichtsrats mit umfassender Erfahrung im globalen Gesundheitswesen, in den Life Sciences und in der Finanzführung börsennotierter Unternehmen weiter stärken. Seine Finanzexpertise und seine Erfahrung an den Kapitalmärkten werden wertvoll sein, während QIAGEN seinen Fokus weiter auf konsequente Umsetzung und eine disziplinierte Kapitalallokation in die renditestärksten Möglichkeiten legt.“ Vorgeschlagene jährliche Dividende QIAGEN schlägt vor, die jährliche Bardividende um 40% auf $0,35 je Stammaktie zu erhöhen. Die erste von Aktionärinnen und Aktionären im Jahr 2025 genehmigte jährliche Dividende lag bei $0,25. QIAGEN führte 2025 seine erste jährliche Dividende als zusätzliche Möglichkeit ein, Kapital an Aktionärinnen und Aktionäre zurückzuzahlen und gleichzeitig die Flexibilität zu bewahren, in langfristiges Wachstum zu reinvestieren. Die vorgeschlagene Dividende für 2026 spiegelt einen disziplinierten Ansatz bei der Kapitalallokation wider, der auf die renditestärksten Möglichkeiten ausgerichtet ist. Dieser umfasst auch organische Investitionen, insbesondere in Forschung und Entwicklung sowie Kommerzialisierungsinitiativen, ebenso wie gezielte M&A-Möglichkeiten. Der erwartete Zeitplan für die Dividende für die an der New York Stock Exchange und an der Frankfurter Wertpapierbörse notierten Aktien lautet wie folgt: Ex-Tag 7. Juli 2026, Stichtag 7. Juli 2026 und Auszahlungstag 14. Juli 2026. Zusätzliche Ermächtigungen für Aktienrückkäufe QIAGEN bittet die Aktionärinnen und Aktionäre außerdem um Zustimmung zu zusätzlichen Ermächtigungen für Aktienrückkäufe als Teil seines disziplinierten Ansatzes bei Kapitalallokation und Kapitalrückzahlungen. Diese Ermächtigungen umfassen Aktienrückkäufe am freien Markt von bis zu 10% des Grundkapitals des Unternehmens sowie einen synthetischen Aktienrückkauf von bis zu $200 Mio. Bei Zustimmung würden diese Ermächtigungen QIAGEN zusätzliche Flexibilität verleihen, Kapital an Aktionärinnen und Aktionäre zurückzuzahlen und gleichzeitig weiter in langfristige Wachstumschancen zu investieren. Ernennungen in den Vorstand Thierry Bernard, Vorstandsvorsitzender, wird bis zur Ernennung eines neuen CEO erneut zur Wahl als Vorstandsmitglied vorgeschlagen. Der Auswahlprozess für die CEO-Nachfolge macht gute Fortschritte. Derzeit wird erwartet, dass ein Nachfolger sein Amt in der zweiten Jahreshälfte 2026 antreten wird. Bis dahin wird Herr Bernard QIAGEN mit der vollen Unterstützung des Aufsichtsrats weiterführen, um Kontinuität und eine klare strategische Ausrichtung sicherzustellen. Roland Sackers, Finanzvorstand, stellt sich ebenfalls erneut als Vorstandsmitglied zur Wiederwahl. Informationen zur Hauptversammlung 2026 Die Hauptversammlung von QIAGEN findet am 24. Juni 2026 um 9:00 Uhr Amsterdamer Zeit im Maaspoort, Oude Markt 30, 5911 HH Venlo, Niederlande, statt. Die Versammlung wird zudem per Live-Webcast im reinen Zuhörmodus übertragen. Aktionärinnen und Aktionäre können über den Webcast nicht abstimmen oder sich in der Versammlung zu Wort melden und werden gebeten, die Unterlagen vorab zu prüfen und ihre Aktien im Vorfeld der Hauptversammlung zu vertreten. Über QIAGEN QIAGEN N.V., eine niederländische Holdinggesellschaft, ist ein weltweit führender Anbieter von Sample-to-Insight-Lösungen, mit denen Kundinnen und Kunden molekulare Informationen aus biologischen Proben extrahieren und analysieren können, die die Bausteine des Lebens enthalten. Unsere Probentechnologien isolieren und verarbeiten DNA, RNA und Proteine aus Blut, Gewebe und anderen Stoffen. Testtechnologien bereiten diese Biomoleküle auf die Analyse vor, während Bioinformatik-Lösungen die Interpretation komplexer Daten unterstützten, um verwertbare Erkenntnisse zu gewinnen. Automationslösungen integrieren diese Schritte in optimierte, kosteneffiziente Workflows. QIAGEN bedient weltweit mehr als 500.000 Kunden in den Bereichen Life Sciences (akademische Forschung, pharmazeutische F&E und industrielle Anwendungen wie Forensik) und Molekulare Diagnostik (klinische Gesundheitsversorgung). Zum 31. März 2026 beschäftigte QIAGEN rund 5.500 Mitarbeiterinnen und Mitarbeiter an über 35 Standorten. Weitere Informationen über QIAGEN finden Sie unter www.qiagen.com. Forward-Looking Statement Einige der Angaben in dieser Pressemitteilung können im Sinne von Section 27A des U.S. Securities Act (US-Wertpapiergesetz) von 1933 in ergänzter Fassung und Section 21E des U.S. Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zukunftsgerichtete Aussagen („forward-looking statements") gelten. Diese Aussagen inklusive solcher über QIAGENs Produkte, den Zeitplan für Entwicklungen, Marketing und/oder regulatorische Genehmigungen, finanzielle und operative Prognosen, Wachstumsstrategien, Kollaborationen und operative Ergebnisse, wie der zu erwartende bereinigte Nettoumsatz und der bereinigte verwässerte Gewinn je Aktie, basieren auf derzeitigen Erwartungen und Annahmen. Diese sind jedoch mit Unsicherheiten und Risiken verbunden. Dazu zählen unter anderem: Risiken im Zusammenhang mit Herausforderungen bei der Steuerung von Wachstum und internationalen Geschäftsaktivitäten (einschließlich Auswirkungen von Währungsschwankungen, Zöllen, Steuergesetzen, regulatorischen Prozessen sowie Abhängigkeiten in der Logistik und Lieferkette); Schwankungen der Betriebsergebnisse und der kommerziellen Entwicklung von Produkten für Kunden in den Bereichen Life Sciences und der klinischen Gesundheitsversorgung, Veränderungen in den Beziehungen zu Kunden, Lieferanten oder strategischen Partnern, das Wettbewerbsumfeld und schneller technologischer Wandel sowie Schwankungen in der Nachfrage nach QIAGEN Produkten (aufgrund von Faktoren wie Wirtschaftslage, Kundenbudgets und Finanzierungszyklen), das Erlangen und die Aufrechterhaltung von Produktzulassungen sowie Herausforderungen bei der Integration von QIAGENs Produkten in Fertigungsprozesse und der Fertigung im großen Maßstab. Weitere Risiken sind die Marktakzeptanz neuer Produkte, die Integration von Akquisitionen, staatliche Maßnahmen, globale oder regionale wirtschaftliche Entwicklungen, Naturkatastrophen, politische Krisen oder Krisen im Bereich der öffentlichen Gesundheit oder sonstige Ereignisse „höherer Gewalt“. Es besteht außerdem keine Garantie, dass der erwartete Nutzen aus 3 Media Release Restrukturierungsprogrammen und Akquisitionen wie erwartet eintritt. Eine ausführlichere Erörterung der Risiken und Unsicherheiten finden Sie im Abschnitt „Risikofaktoren“ in unserem aktuellen Annual Report Form 20-F und anderen Berichten, die bei der US-Börsenaufsichtsbehörde (U.S. Securities and Exchange Commission) eingereicht oder dieser zur Verfügung gestellt wurden. Source: QIAGEN N.V.
Category: Corporate Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260511643963/de/ Public Relations
E-Mail: pr@QIAGEN.com Investor Relations
E-Mail: ir@QIAGEN.com Original: QIAGEN plant die Ernennung von Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, setzt die Neuausrichtung der Aufsichtsratsstruktur fort und schlägt höhere Kapitalrückzahlungen auf der Hauptversammlung 2026 vor

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlookApril 27, 2026 4:16 PM
Business Wire
Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.


For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER growth. Adjusted diluted EPS are expected to be $0.54 on a reported basis and $0.54 CER, in line with the outlook.


QIAGEN’s growth pillars together grew 4% CER compared to Q1 2025. Sample technologies delivered 9% CER growth compared with Q1 2025, and 3% CER growth excluding the Parse acquisition, supported by demand for automated consumables and instrument placements. QIAcuity digital PCR delivered double-digit CER sales growth on higher consumables and instrument sales over the year-ago period. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. QIAstat-Dx sales declined 1% CER as expected against tough prior-year results. Consumables sales rose despite a weaker respiratory season on double-digit CER growth from recently launched Gastrointestinal and Meningitis panels in the U.S., while instrument placements continued at a good level.


QuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East. Trends remained solid in other patient testing groups. QIAGEN now expects QuantiFERON full-year 2026 sales to be unchanged at CER compared with 2025 sales of $503 million.


QIAGEN has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include headwinds from reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER). QIAGEN expects stronger growth trends in the second half of 2026, supported by the end of headwinds from the discontinuation of NeuMoDx and Dialunox, benefits from recent and planned product launches, sequential improvement in QuantiFERON sales and contributions from the Parse acquisition tracking ahead of the original target for 2026.


For Q2 2026, QIAGEN expects net sales to decline approximately 2% CER from $534 million in Q2 2025. Adjusted diluted EPS are expected to be at least $0.60 CER compared with $0.60 in Q2 2025.


“QIAGEN made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies, QIAcuity and QIAGEN Digital Insights,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QuantiFERON was affected by the significant decline in immigration testing demand, but we view this as a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing. We are focused on executing against our updated 2026 targets and positioning QIAGEN for faster growth in the second half of 2026.”


“Our profitability for the first quarter reflected disciplined execution in a challenging environment, as we managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements and measures to ensure reliable product supply,” said Roland Sackers, Chief Financial Officer of QIAGEN. “We are focused on delivering solid profitable growth through efficiency gains combined with disciplined capital allocation and targeted investments that strengthen QIAGEN’s long-term growth potential and create value for shareholders.”


Preliminary sales by product groups




In $ millions






 






Q1








 






2026




sales






 






2025




sales






 






Change






 






CER change








 






 






 






 






 






 






 






 






 








Sample technologies






 






170






 






150






 






+13 %






 






+9 %








Diagnostic solutions






 






185






 






187






 






-1 %






 






-4 %








Of which QuantiFERON






 






113






 






116






 






-3 %






 






-5 %








Of which QIAstat-Dx






 






36






 






34






 






+4 %






 






-1 %








Of which NeuMoDx






 






—






 






6






 






-100 %






 






-100 %








Of which Other






 






36






 






31






 






+19 %






 






+15 %








PCR/Nucleic acid amplification






 






69






 






76






 






-9 %






 






-13 %








Genomics/NGS






 






57






 






53






 






+6 %






 






+4 %








Other






 






12






 






18






 






-31 %






 






-31 %








Total net sales






 






492






 






483






 






+2 %






 






-1 %







Tables may have rounding differences. Percentage changes are to prior-year periods.


Preliminary Q1 2026 results conference call on Tuesday, April 28, 2026


A conference call to discuss the preliminary Q1 2026 results and updated full-year 2026 outlook is scheduled for Tuesday, April 28, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. A live audio webcast will be available in the Investor Relations section of the QIAGEN website (www.qiagen.com), with a recording accessible after the event. The accompanying presentation will be published at the same time as this press release under "Events and Presentations" in the same section.


Full Q1 2026 results publication on May 6, 2026


QIAGEN plans to publish full Q1 2026 results on May 6, 2026, shortly after 22:05 Frankfurt Time / 21:05 London Time / 16:05 New York Time.


QuantiFERON Spotlight Session on May 7, 2026


As previously announced, QIAGEN plans to hold a virtual Spotlight Session to provide insights into our strategic priorities for QuantiFERON and an update on the latest product enhancements. The online event, which is a new format that builds on the recent Deep Dives series, is scheduled for Thursday, May 7, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. Registration details and further information about the webcast are available in the Investor Relations section of the QIAGEN website (www.qiagen.com), under Events and Presentations (https://corporate.qiagen.com/English/investor-relations/events-and-presentations/), with a recording accessible after the event.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.


Forward-Looking Statement


Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.


Source: QIAGEN N.V.


Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427495954/en/
Investor Relations

e-mail: ir@QIAGEN.com


Public Relations

e-mail: pr@QIAGEN.com


Original: QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

QIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026: Bereinigter Gewinn je Aktie entspricht bei gemischten Umsatztrends den Erwartungen; Jahresprognose 2026 aktualisiertApril 27, 2026 4:16 PM
Business Wire
Probentechnologien, QIAcuity und QDI verzeichnen solides Wachstum; Umsätze mit QuantiFERON von deutlich geringerer Nachfrage bei Immigrationsuntersuchungen beeinflusst


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die vorläufigen Ergebnisse für das erste Quartal 2026 bekannt gegeben. Das Unternehmen verzeichnete weiterhin eine starke Profitabilität mit einem bereinigten verwässerten Gewinn je Aktie, der den Erwartungen entsprach. Die Umsatzentwicklung war gemischt, wobei geringere Umsätze bei QuantiFERON und eine zurückhaltende Nachfrage seitens der US-Kunden im Bereich Life Sciences das solide Wachstum in anderen Teilen des Portfolios aufhoben.


Im ersten Quartal 2026 belief sich der vorläufige Konzernumsatz auf $492 Mio., was einem Anstieg von 2% auf berichteter Basis und einem Rückgang von 1% bei konstanten Wechselkursen (CER) entsprach, verglichen mit einer Prognose von mindestens 1% CER-Wachstum. Der bereinigte verwässerte Gewinn je Aktie wird voraussichtlich $0,54 auf berichteter Basis und $0,54 bei konstanten Wechselkursen betragen, was den Erwartungen entspricht.


QIAGENs Wachstumsträger verzeichneten zusammen ein CER-Wachstum von 4% verglichen mit dem ersten Quartal 2025. Der Bereich Probentechnologien erzielte dabei ein Wachstum von 9% (CER) gegenüber dem Vorjahresquartal und ein Wachstum von 3% (CER) ohne Berücksichtigung der Übernahme von Parse, gestützt durch die Nachfrage nach automatisierten Verbrauchsmaterialien und der Platzierung von Instrumenten. QIAcuity digital PCR erzielte ein zweistelliges CER-Wachstum aufgrund höherer Umsätze sowohl bei Verbrauchsmaterialien als auch bei Geräten verglichen mit dem Vorjahreszeitraum. QIAGEN Digital Insight (QDI) verzeichnete solide einstellige Zuwächse, allen voran im Bereich der klinischen Bioinformatik. Die Umsätze mit QIAstat-Dx gingen wie erwartet um 1% (CER) gegenüber den starken Ergebnissen des Vorjahres zurück. Die Umsätze mit Verbrauchsmaterialien wuchsen hingegen trotz einer schwächeren Erkältungssaison dank eines zweistelligen CER-Wachstums durch die kürzlich in den USA eingeführten Panels für Magen-Darm-Erkrankungen und Meningitis. Auch die Instrumentenverkäufe blieben weiterhin auf einem guten Niveau.


Die Umsätze mit QuantiFERON gingen gegenüber dem ersten Quartal 2025 um 5% (CER) zurück, hauptsächlich aufgrund eines deutlichen Nachfragerückgangs nach Tests für Einwanderer in den USA und im Nahen Osten. Bei anderen Patientengruppen blieben die Nachfragetrends hingegen stabil. QIAGEN geht derzeit davon aus, dass der Gesamtumsatz mit QuantiFERON im Jahr 2026 auf Basis konstanter Wechselkurse unverändert bleiben wird im Vergleich zum Umsatz von $503 Mio. im Jahr 2025.


QIAGEN hat seinen Ausblick für das Gesamtjahr 2026 aktualisiert und erwartet nun ein Umsatzwachstum von etwa 1-2% (CER) (zuvor mindestens 5% CER-Wachstum). Wichtige Einflussfaktoren sind hierbei die rückläufige Nachfrage nach QuantiFERON-Tests für Immigrationsuntersuchungen, die anhaltende Vorsicht bei Life-Sciences-Kundinnen und Kunden in den USA sowie zunehmende geopolitische Unsicherheiten. Der bereinigte verwässerte Gewinn je Aktie wird nun auf mindestens $2,43 (CER) geschätzt (zuvor mindestens $2,50 (CER)). QIAGEN erwartet stärkere Wachstumsdynamiken in der zweiten Jahreshälfte 2026, gestützt durch das Wegfallen negativer Effekte aufgrund der Einstellung von NeuMoDx und Dialunox, Zuwächse aus kürzlich erfolgten und geplanten Produkteinführungen, eine schrittweise Verbesserung der QuantiFERON-Umsätze sowie Beiträge aus der Übernahme von Parse, die über dem ursprünglichen Ziel für 2026 liegen.


Für das zweite Quartal 2026 erwartet QIAGEN einen Umsatzrückgang von ca. 2% (CER) gegenüber $534 Mio. im zweiten Quartal 2025. Der bereinigte verwässerte Gewinn je Aktie wird voraussichtlich mindestens $0,60 (CER) betragen, verglichen mit $0,60 im Vorjahresquartal.


„QIAGEN hat im ersten Quartal in vielen Teilen des Portfolios wichtige Fortschritte erzielt, angeführt von einem soliden Umsatzwachstum in den Bereichen Probentechnologien, QIAcuity und QIAGEN Digital Insights“, sagte Thierry Bernard, Chief Executive Officer von QIAGEN. „QuantiFERON war von einem deutlichen Nachfragerückgang bei Einwanderungstests betroffen, wir betrachten dies jedoch als Neubewertung der Nachfrage innerhalb dieser Zielgruppe im Jahr 2026 und nicht als eine Veränderung des langfristigen Gesamtpotenzials für Tests auf latente Tuberkulose. Wir konzentrieren uns darauf, unsere aktualisierten Ziele für 2026 umzusetzen und QIAGEN für ein schnelleres Wachstum in der zweiten Jahreshälfte 2026 zu positionieren.“


„Unsere Profitabilität im ersten Quartal spiegelte unsere disziplinierte Umsetzung in einem herausfordernden Umfeld wider. Wir haben dabei sowohl die Auswirkungen unterstützender Portfolioinvestitionen als auch die Herausforderungen durch Zölle, Währungsschwankungen und Maßnahmen zur Sicherstellung einer zuverlässigen Produktversorgung erfolgreich gesteuert“, sagte Roland Sackers, Chief Financial Officer von QIAGEN. „Unser Fokus liegt darauf, durch Effizienzsteigerungen in Verbindung mit einer disziplinierten Kapitalallokation und gezielten Investitionen ein solides, profitables Wachstum zu erzielen, das QIAGENs langfristiges Wachstumspotenzial stärkt und einen Mehrwert für unsere Aktionärinnen und Aktionäre schafft.“


Vorläufige Umsätze nach Produktgruppen




In Millionen $






 






Q1








 






Umsatz

2026






 






Umsatz

2025






 






Veränd.






 






Veränd.

CER








 






 






 






 






 






 






 






 






 








Probentechnologien






 






170






 






150






 






+13 %






 






+9 %








Diagnostiklösungen






 






185






 






187






 






-1 %






 






-4 %








davon QuantiFERON






 






113






 






116






 






-3 %






 






-5 %








davon QIAstat-Dx






 






36






 






34






 






+4 %






 






-1 %








davon NeuMoDx






 






—






 






6






 






-100 %






 






-100 %








davon Sonstige






 






36






 






31






 






+19 %






 






+15 %








PCR / Nukleinsäure-Amplifikationsverfahren






 






69






 






76






 






-9 %






 






-13 %








Genomik /NGS






 






57






 






53






 






+6 %






 






+4 %








Sonstige






 






12






 






18






 






-31 %






 






-31 %








Gesamtumsatz






 






492






 






483






 






+2 %






 






-1 %







Die Tabellen können Rundungseffekte enthalten. Die Veränderungen in Prozent beziehen sich auf die Vorjahreszeiträume.


Telefonkonferenz zu den vorläufigen Ergebnissen des ersten Quartals 2026 am Dienstag, den 28. April 2026


Eine Telefonkonferenz zur Erörterung der vorläufigen Ergebnisse des ersten Quartals 2026 und des aktualisierten Jahresausblicks für 2026 ist für Dienstag, den 28. April 2026, um 15:30 MEZ / 14:30 GMT / 9:30 EST geplant. Die Telefonkonferenz kann unter dem Registereintrag „Investor Relations“ auf der Website von QIAGEN (www.qiagen.com) als Audio-Stream live mitverfolgt werden und ist danach als Aufzeichnung verfügbar. Eine Hintergrundpräsentation soll kurz vor der Telefonkonferenz zur Verfügung stehen unter: https://corporate.qiagen.com/English/investor-relations/events-and-presentations/.


Veröffentlichung der vollständigen Ergebnisse für das erste Quartal 2026 am 6. Mai 2026


QIAGEN plant, die vollständigen Ergebnisse für das erste Quartal 2026 am 6. Mai 2026 kurz nach 22:05 MEZ / 21:05 GMT / 16:05 EST zu veröffentlichen.


QuantiFERON Spotlight-Session am 7. Mai 2026


Wie bereits angekündigt, plant QIAGEN die Durchführung einer virtuellen Spotlight-Session, um Einblicke in seine strategischen Prioritäten rund um QuantiFERON zu geben und über die neusten Produktverbesserungen zu informieren. Die Online-Veranstaltung, ein neues Format, das auf der aktuellen Reihe von Deep Dives aufbaut, ist für Donnerstag, den 7. Mai 2026, um 15:30 MEZ / 14:30 GMT / 9:30 EST geplant. Details zur Anmeldung und weitere Informationen zum Webcast finden Sie im Bereich „Investor Relations“ auf der Website von QIAGEN (www.qiagen.com) unter „Events and Presentations“ (https://corporate.qiagen.com/English/investor-relations/events-and-presentations/), wo nach der Veranstaltung auch eine Aufzeichnung zur Verfügung stehen wird.


Über QIAGEN


QIAGEN N.V., eine niederländische Holdinggesellschaft, ist ein weltweit führender Anbieter von Sample-to-Insight-Lösungen, mit denen Kundinnen und Kunden molekulare Informationen aus biologischen Proben extrahieren und analysieren können, die die Bausteine des Lebens enthalten. Unsere Probentechnologien isolieren und verarbeiten DNA, RNA und Proteine aus Blut, Gewebe und anderen Stoffen. Testtechnologien bereiten diese Biomoleküle auf die Analyse vor, während Bioinformatik-Lösungen die Interpretation komplexer Daten unterstützten, um verwertbare Erkenntnisse zu gewinnen. Automationslösungen integrieren diese Schritte in optimierte, kosteneffiziente Workflows. QIAGEN bedient weltweit mehr als 500.000 Kunden in den Bereichen Life Sciences (akademische Forschung, pharmazeutische F&E und industrielle Anwendungen wie Forensik) und Molekulare Diagnostik (klinische Gesundheitsversorgung). Zum 31. März 2026 beschäftigte QIAGEN rund 5.500 Mitarbeiterinnen und Mitarbeiter an über 35 Standorten. Weitere Informationen über QIAGEN finden Sie unter www.qiagen.com.


Forward-Looking Statement


Einige der Angaben in dieser Pressemitteilung können im Sinne von Section 27A des U.S. Securities Act (US-Wertpapiergesetz) von 1933 in ergänzter Fassung und Section 21E des U.S. Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zukunftsgerichtete Aussagen („forward-looking statements") gelten. Diese Aussagen inklusive solcher über QIAGENs Produkte, den Zeitplan für Entwicklungen, Marketing und/oder regulatorische Genehmigungen, finanzielle und operative Prognosen, Wachstumsstrategien, Kollaborationen und operative Ergebnisse, wie der zu erwartende bereinigte Nettoumsatz und der bereinigte verwässerte Gewinn je Aktie, basieren auf derzeitigen Erwartungen und Annahmen. Diese sind jedoch mit Unsicherheiten und Risiken verbunden. Dazu zählen unter anderem: Risiken im Zusammenhang mit Herausforderungen bei der Steuerung von Wachstum und internationalen Geschäftsaktivitäten (einschließlich Auswirkungen von Währungsschwankungen, Zöllen, Steuergesetzen, regulatorischen Prozessen sowie Abhängigkeiten in der Logistik und Lieferkette); Schwankungen der Betriebsergebnisse und der kommerziellen Entwicklung von Produkten für Kunden in den Bereichen Life Sciences und der klinischen Gesundheitsversorgung, Veränderungen in den Beziehungen zu Kunden, Lieferanten oder strategischen Partnern, das Wettbewerbsumfeld und schneller technologischer Wandel sowie Schwankungen in der Nachfrage nach QIAGEN Produkten (aufgrund von Faktoren wie Wirtschaftslage, Kundenbudgets und Finanzierungszyklen), das Erlangen und die Aufrechterhaltung von Produktzulassungen sowie Herausforderungen bei der Integration von QIAGENs Produkten in Fertigungsprozesse und der Fertigung im großen Maßstab. Weitere Risiken sind die Marktakzeptanz neuer Produkte, die Integration von Akquisitionen, staatliche Maßnahmen, globale oder regionale wirtschaftliche Entwicklungen, Naturkatastrophen, politische Krisen oder Krisen im Bereich der öffentlichen Gesundheit oder sonstige Ereignisse „höherer Gewalt“. Es besteht außerdem keine Garantie, dass der erwartete Nutzen aus Restrukturierungsprogrammen und Akquisitionen wie erwartet eintritt. Eine ausführlichere Erörterung der Risiken und Unsicherheiten finden Sie im Abschnitt „Risikofaktoren“ in unserem aktuellen Annual Report Form 20-F und anderen Berichten, die bei der US-Börsenaufsichtsbehörde (U.S. Securities and Exchange Commission) eingereicht oder dieser zur Verfügung gestellt wurden.


Source: QIAGEN N.V.


Category: Corporate

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260427082087/de/
QIAGEN Kontakte:

Investor Relations

e-mail: ir@QIAGEN.com


Public Relations

e-mail: pr@QIAGEN.com


Original: QIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026: Bereinigter Gewinn je Aktie entspricht bei gemischten Umsatztrends den Erwartungen; Jahresprognose 2026 aktualisiert

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026April 16, 2026 4:05 PM
Business Wire

Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis




QIAsymphony Connect will serve as a foundation for lab workflows, enabling standardized nucleic acid extraction for clinical and translational research




Introduction of the QIAGEN Discovery Platform, an AI-grounding solution to power downstream AI applications and support drug discovery for research purposes



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260416549758/en/QIAGEN to showcase QIAsymphony Connect among other solutions addressing key oncology research needs
“Cancer research and molecular diagnostics are increasingly constrained by fragmented workflows, variability in sample processing and the growing complexity of multi-omics data,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “At AACR, we are demonstrating how QIAGEN’s Sample to Insight portfolio helps standardize critical steps from sample preparation through data interpretation, enabling more consistent results, improved reproducibility and more confident insights from complex biological data.”


At the AACR Annual Meeting 2026, QIAGEN will showcase applications across key stages of the oncology workflow, from sample preparation to genomic profiling and data interpretation:



Sample technologies: New instruments and kits highlighting Parse single-cell solutions


QIAsymphony Connect: The upcoming IVD QIAsymphony Connect will support oncology workflows in laboratories around the world. This scalable automation platform for clinical molecular testing builds on over 3,300 placements of the established QIAsymphony system to automate IVD sample extraction, improve laboratory productivity, enhance sample traceability and process safety and deliver highly concentrated nucleic acid for sensitive assays. As molecular testing expands across oncology and other applications, QIAsymphony Connect will help laboratories standardize complex workflows while reducing hands-on time and supporting reproducible, high-quality results.



QIAsprint Connect: Following its launch at the SLAS 2026 meeting in February, QIAsprint Connect for research use only is now progressing through commercialization as QIAGEN’s new high-throughput automation platform for research laboratories. The compact benchtop system enables automated purification of up to 192 DNA or RNA samples per run, supports validated and customizable workflows, and helps laboratories scale sample processing while reducing plastic use and packaging volume.



Evercode single-cell analysis: Parse Biosciences, a QIAGEN company, will highlight at AACR its Evercode Whole Transcriptome portfolio, including the recently launched v4 kit with higher cell recovery, higher sensitivity and shorter workflow with lower sequencing budget. Parse will also showcase the Evercode Whole Transcriptome FFPE kit, now shipping after the successful completion of an early access program with select partners. The Evercode WT FFPE enables unbiased whole transcriptome single cell RNA sequencing of millions of nuclei from FFPE-preserved tissues using Parse's novel split-pool combinatorial barcoding method.






Genomic profiling: New QIAseq research panels for use on next-generation sequencers (NGS)


QIAseq xHYB HRD Panel: Developed with Myriad Genetics, the QIAseq xHYB HRD Panel is designed to support research into homologous recombination deficiency as an important cancer biomarker for research applications. The assay combines QIAGEN’s hybrid capture technology with Myriad analytics to support assessment of genomic instability, and has shown high concordance with the Myriad myChoice CDx HRD assay.



QIAseq xHYB Trinity DNA/RNA Kit: This new kit enables comprehensive genomic profiling from DNA, RNA or both in a single research workflow using the AVITI platform from Element Biosciences. Designed for use with Element’s Trinity sequencing workflow, it helps streamline target enrichment through a shorter hybridization step, fewer manual cleanup steps and no post-enrichment PCR, reducing hands-on time while supporting high on-target rates and confident variant detection for research applications.






Data interpretation: New AI-grounding platform for unified drug discovery support for research purposes


QIAGEN Discovery Platform: QIAGEN Digital Insights, the bioinformatics business of QIAGEN, will introduce the QIAGEN Discovery Platform at AACR as an AI-grounding solution for drug discovery. The platform is designed to bring together biological knowledge, omics data and advanced analytics to support oncology research, with future implementation of AI functions and integration with downstream AI analysis. The platform will be presented through demonstrations and spotlight sessions at the AACR meeting.






To learn more about QIAGEN’s Sample to Insight portfolio, visit Booth #3547 at the AACR Annual Meeting 2026 in San Diego from April 17–22, or go to www.qiagen.com/oncology-meeting.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.


Forward-Looking Statement


Certain statements contained in this release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches, leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.


Source: QIAGEN N.V.


Category: Oncology

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416549758/en/
QIAGEN contacts:

Public Relations

e-mail: pr@QIAGEN.com

Investor Relations

e-mail: ir@QIAGEN.com


Original: QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx PanelApril 14, 2026 4:05 PM
Business Wire

QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies



CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making



Launch marks QIAGEN’s expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.


The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside additional technologies supporting laboratory workflows, clinical decision-making and the development of Laboratory Developed Tests (LDTs).


The QIAstat-Dx BCID GPF Plus AMR Panel enables laboratories to identify 20 gram-positive bacterial and fungal pathogen targets (GPF) and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies. This launch expands the QIAstat-Dx portfolio beyond respiratory, gastrointestinal and meningitis / encephalitis testing into bloodstream infection applications.


In bloodstream infections, timely identification of pathogens and resistance markers is critical, as treatment decisions often need to be made quickly. By delivering results in about one hour, the QIAstat-Dx BCID GPF Plus AMR Panel is designed to support laboratory workflows while providing clinically relevant information for patient management, antimicrobial stewardship and infection control efforts.


“Rapid identification of pathogens and resistance markers is important in bloodstream infections, where treatment decisions often need to be made quickly,” said Nadia Aelbrecht, Vice President, Head of Infectious Diseases at QIAGEN. “With this launch, we are extending the QIAstat-Dx portfolio into bloodstream infection testing and giving laboratories a new option to generate clinically relevant results from positive blood cultures and colonies. We plan to further expand this offering with additional panels in development, including those targeting gram-negative pathogens.”


QIAstat-Dx integrates sample preparation, molecular testing and data analysis into a single workflow. The systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.


For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/applications/syndromic-testing.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.


Forward-Looking Statement


Certain statements contained in this release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches, leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.


Source: QIAGEN N.V.


Category: Infectious Diseases

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414262531/en/
QIAGEN contacts:


Public Relations

e-mail: pr@QIAGEN.com


Investor Relations

e-mail: ir@QIAGEN.com


Original: QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

Qiagen Announces Form 20-F Annual Report Filing for 2025 ResultsMarch 20, 2026 7:30 AM
Business Wire
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.


QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to ir@qiagen.com.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.


Source: QIAGEN N.V.


Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20260320968222/en/
Investor Relations

e-mail: ir@QIAGEN.com


Public Relations

e-mail: pr@QIAGEN.com


Original: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB PreventionMarch 19, 2026 4:05 PM
Business Wire

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings



Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV



CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations.


The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention globally. The global QuantiFERON World TB Day event will take place online on March 24, 2026, with two identical sessions to enable participation across regions. To learn more and reserve a free spot, visit https://worldtbday.qiagen.com/.


A study recently published in BMC Public Health evaluated TB infection screening strategies among adults living with HIV in Thailand and found that QFT-Plus testing reduced the modeled lifetime risk of progression to active TB by 41% compared with the tuberculin skin test (TST), while also lowering overall lifetime healthcare costs. More accurate detection of TB infection can help clinicians initiate preventive therapy earlier and support more efficient use of healthcare resources.


This study builds on a strong and expanding body of clinical data supporting the use of QFT-Plus across diverse patient populations. More than 2,500 published studies have demonstrated the test’s performance, with over 125 million QuantiFERON-TB tests used worldwide, including in populations at increased risk of developing active TB disease such as those receiving immunosuppressive therapies. Accurate detection of TB infection in these groups remains critical to enable timely preventive treatment and reduce the risk of disease progression.


“These findings strengthen an already extensive foundation of evidence supporting QuantiFERON as a reliable solution for TB infection detection,” said Nadia Aelbrecht, Vice President and Head of Infectious Diseases at QIAGEN. “Through QuantiFERON and our collaboration with the global TB community, we aim to support clinicians, laboratories and public health authorities with reliable tools that help identify infection earlier and guide preventive treatment across different settings, laboratory workloads and various high risk groups.”


TB remains one of the world’s deadliest infectious diseases despite being preventable and treatable. According to the World Health Organization, an estimated 10 million people develop active TB each year. Individuals with weakened immune systems face significantly higher risks of progressing from TB infection to active disease.


Against this backdrop, the CPD-accredited QuantiFERON World TB Day program will bring together international experts in TB diagnostics, clinical care and public health to discuss advances in TB infection detection and prevention.


Sessions will address the performance of TB infection testing in immunocompromised patients, the role of preventive treatment in national TB control programs, and emerging insights from clinical research and public health initiatives. Speakers will also share perspectives from clinical practice, public health programs and TB survivors.


QIAGEN continues to invest in expanding the QuantiFERON portfolio and improving laboratory workflows for TB infection testing. QIAGEN is advancing development of a fifth generation of QuantiFERON designed to further enhance performance, while also exploring the use of AI to help identify individuals with latent TB infection who are at higher risk of progressing to active disease. Early research indicates that AI-driven models combining QFT-Plus results with clinical factors may help improve risk prediction and support more targeted preventive treatment. In addition, QIAGEN is strengthening its automation offering through its partnership with Diasorin, enabling laboratories to run QuantiFERON testing on LIAISON automated immunodiagnostic systems to support scalable, high-throughput TB infection testing.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.


Forward-Looking Statement


Certain statements contained in this release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches, leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.


Source: QIAGEN N.V.


Category: Infectious Diseases

View source version on businesswire.com: https://www.businesswire.com/news/home/20260319519055/en/
Public Relations

e-mail: pr@QIAGEN.com


Investor Relations

e-mail: ir@QIAGEN.com


Original: QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vorMarch 19, 2026 4:05 PM
Business Wire

Neue Studie unterstützt den Einsatz von QuantiFERON-TB Gold Plus bei immungeschwächten Personen und anderen Hochrisikogruppen in verschiedenen Settings



Ergebnisse zeigen, dass der QuantiFERON-Test bei Menschen mit HIV im Vergleich zum Tuberkulin-Hauttest Kostenvorteile bietet



Das CPD-akkreditierte Online-Programm zu QuantiFERON bringt zum Welttuberkulosetag am 24. März internationale Expertinnen und Experten zusammen, um die Diagnose und Prävention von TB sowie den wissenschaftlichen Austausch zu fördern



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Veröffentlichung neuer klinischer und gesundheitsökonomischer Daten bekannt gegeben, die den Einsatz seines QuantiFERON-TB Gold Plus-Bluttests (QFT-Plus) zum Nachweis von Tuberkulose (TB)-Infektionen unterstützen, insbesondere bei immungeschwächten Personen und anderen Hochrisikogruppen.


Die Bekanntgabe erfolgt im Vorfeld des Welttuberkulosetags und unterstreicht die anhaltende Bedeutung einer weltweiten Verbesserung der Tuberkulose-Erkennung und -Prävention. Die globale QuantiFERON-Veranstaltung zum Welttuberkulosetag findet am 24. März 2026 online statt und wird in zwei identischen Sessions angeboten, um die Teilnahme aus verschiedenen Regionen zu ermöglichen. Weitere Informationen und eine kostenfreie Anmeldung sind unter https://worldtbday.qiagen.com/ verfügbar.


Eine kürzlich in BMC Public Health veröffentlichte Studie untersuchte Screening-Strategien für TB-Infektionen bei Erwachsenen mit HIV in Thailand und zeigte, dass QFT-Plus das modellierte Risiko, im Laufe des Lebens eine aktive TB-Erkrankung zu entwickeln, im Vergleich zum Tuberkulin-Hauttest (TST) um 41% reduzierte und gleichzeitig zu einer Verringerung der gesamten lebenslangen Gesundheitskosten führte. Eine präzisere Erkennung von TB-Infektionen kann dazu beitragen, dass präventive Behandlungen früher eingeleitet und Gesundheitsressourcen effizienter eingesetzt werden können.


Diese Studie stützt sich auf einen soliden und stetig wachsenden Bestand an klinischen Daten, die den Einsatz von QFT-Plus in unterschiedlichen Patientengruppen belegen. Mehr als 2.500 veröffentlichte Studien haben die Leistungsfähigkeit des Tests bereits bestätigt, wobei weltweit über 125 Millionen QuantiFERON-TB-Tests durchgeführt wurden, darunter auch bei Bevölkerungsgruppen mit erhöhtem Risiko, eine aktive TB-Erkrankung zu entwickeln, etwa bei Personen, die immunsuppressive Therapien erhalten. Ein genauer Nachweis von TB-Infektionen in diesen Gruppen ist nach wie vor entscheidend, um eine rechtzeitige präventive Behandlung zu ermöglichen und das Risiko eines Fortschreitens der Erkrankung zu verringern.


„Diese Ergebnisse stärken die bereits umfangreiche Evidenzbasis für QuantiFERON als zuverlässige Lösung für den Nachweis von TB-Infektionen“, sagte Nadia Aelbrecht, Vice President und Head of Infectious Diseases bei QIAGEN. „Mit QuantiFERON und in Zusammenarbeit mit der globalen TB-Community möchten wir Ärztinnen und Ärzte, Labore sowie Gesundheitsbehörden mit verlässlichen Lösungen unterstützen, die dazu beitragen, Infektionen früher zu erkennen und präventive Behandlungen in unterschiedlichen Settings, bei unterschiedlicher Laborauslastung und für verschiedene Hochrisikogruppen zu steuern.“


Tuberkulose ist nach wie vor eine der tödlichsten Infektionskrankheiten weltweit, obwohl sie vermeidbar und behandelbar ist. Nach Angaben der Weltgesundheitsorganisation erkranken jedes Jahr schätzungsweise 10 Millionen Menschen an aktiver TB. Personen mit geschwächtem Immunsystem haben ein deutlich höheres Risiko, dass sich eine TB-Infektion zu einer aktiven Erkrankung entwickelt.


Vor diesem Hintergrund bringt das CPD-akkreditierte QuantiFERON-Programm zum Welttuberkulosetag internationale Expertinnen und Experten aus den Bereichen TB-Diagnostik, klinische Versorgung und dem öffentlichen Gesundheitswesen zusammen, um über Fortschritte bei der Erkennung und Prävention von TB-Infektionen zu diskutieren.


Die Veranstaltung befasst sich unter anderem mit der Leistungsfähigkeit von TB-Tests bei immungeschwächten Patientinnen und Patienten, der Rolle präventiver Behandlungen in nationalen Programmen zur TB-Kontrolle sowie mit neuen Erkenntnissen aus der klinischen Forschung und öffentlichen Gesundheitsinitiativen. Die Referentinnen und Referenten werden zudem Einblicke in die klinische Praxis, öffentliche Gesundheitsprogramme und die Erfahrungen von TB-Überlebenden geben.


QIAGEN investiert weiterhin in den Ausbau seines QuantiFERON-Portfolios und in die Verbesserung von Labor-Workflows für die TB-Testung. QIAGEN treibt die Entwicklung einer fünften Generation von QuantiFERON voran, die die Leistungsfähigkeit weiter verbessern soll, und untersucht gleichzeitig den Einsatz von Künstlicher Intelligenz, um Personen mit latenter TB-Infektion zu identifizieren, bei denen ein erhöhtes Risiko für den Übergang in eine aktive Erkrankung besteht. Erste Forschungsergebnisse zeigen, dass KI-gestützte Modelle, die QFT-Plus Ergebnisse mit klinischen Faktoren kombinieren, die Risikovorhersage verbessern und gezieltere präventive Behandlungen unterstützen können. Darüber hinaus stärkt QIAGEN sein Automationsangebot durch die Partnerschaft mit Diasorin. Dadurch können Labore QuantiFERON-Tests auf den automatisierten LIAISON-Immundiagnostik-Systemen durchführen, so dass skalierbare TB-Testungen mit hohem Durchsatz ermöglicht werden.


Über QIAGEN


QIAGEN N.V., eine niederländische Holdinggesellschaft, ist ein weltweit führender Anbieter von Sample-to-Insight-Lösungen, mit denen Kundinnen und Kunden molekulare Informationen aus biologischen Proben extrahieren und analysieren können, die die Bausteine des Lebens enthalten. Unsere Probentechnologien isolieren und verarbeiten DNA, RNA und Proteine aus Blut, Gewebe und anderen Stoffen. Testtechnologien bereiten diese Biomoleküle auf die Analyse vor, während Bioinformatik-Lösungen die Interpretation komplexer Daten unterstützten, um verwertbare Erkenntnisse zu gewinnen. Automationslösungen integrieren diese Schritte in optimierte, kosteneffiziente Workflows. QIAGEN bedient weltweit mehr als 500.000 Kunden in den Bereichen Life Sciences (akademische Forschung, pharmazeutische F&E und industrielle Anwendungen wie Forensik) und Molekulare Diagnostik (klinische Gesundheitsversorgung). Zum 31. Dezember 2025 beschäftigte QIAGEN rund 5.700 Mitarbeiterinnen und Mitarbeiter an über 35 Standorten. Weitere Informationen über QIAGEN finden Sie unter www.qiagen.com.


Source: QIAGEN N.V.


Category: Infectious Diseases

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260319144815/de/
Public Relations

e-mail: pr@QIAGEN.com


Investor Relations

e-mail: ir@QIAGEN.com


Original: QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing SystemMarch 10, 2026 5:05 PM
Business Wire

FDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months



Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system



QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system.


With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on QIAstat-Dx Rise, the high-throughput version of the QIAstat-Dx system. Both versions support comprehensive syndromic testing with panels designed to detect multiple pathogens associated with similar symptoms in a single test, as well as targeted Mini panels that focus on a defined group of pathogens.


Expanding menu for the first fully automated syndromic testing platform


QIAGEN launched QIAstat-Dx Rise in the U.S. in September 2025 to address growing demand for higher testing capacity and increased automation in molecular diagnostics laboratories. The system features a smart drawer design that automates cartridge loading and unloading, helping users reduce manual handling and increase walkaway time.


With up to eight analytical modules, QIAstat-Dx Rise can process up to 160 tests per day. Laboratories can run 16 samples in a batch while maintaining dedicated urgent slots for priority samples, supporting fast turnaround times when timely clinical decisions are required.


“This milestone further strengthens the positioning of QIAstat-Dx Rise as a fully automated platform for syndromic testing in the U.S. and other countries around the world,” said Nadia Aelbrecht, Vice President and Head of Infectious Diseases at QIAGEN. “Laboratories can now consolidate respiratory and gastrointestinal testing on one system. By combining scalable automation with detailed molecular insights, QIAstat-Dx systems can help laboratories streamline operations while supporting timely treatment decisions.”


Flexible panel options designed for a seamless testing solution


The FDA clearance includes:



QIAstat-Dx Gastrointestinal Panel 2, detecting 16 bacterial, viral and parasitic pathogens from a single stool sample (Para-Pak C&S or FecalSwab), including clinically relevant Shiga toxin-producing E. coli (STEC) subtypes such as stx2f.



QIAstat-Dx GI Panel 2 Mini B and Mini B&V, providing targeted detection of five gastrointestinal pathogens, including STEC.



Results are delivered in about one hour using real-time PCR technology, which detects genetic material from pathogens. The system requires less than one minute of hands-on time per test. QIAstat-Dx provides cycle threshold (Ct) values and amplification curves in the same reaction, giving laboratories additional context in cases of co-infection. Results are displayed directly on the instrument touchscreen without requiring additional software.


This U.S. regulatory clearance represents the ninth FDA clearance for the QIAstat-Dx portfolio in the past 24 months and expands the U.S. portfolio to six panels cleared for the QIAstat-Dx family. It also follows the recent FDA authorization of QIAstat-Dx Rise for use with QIAstat-Dx Respiratory Panels and the addition of the FecalSwab® sample type across all QIAstat-Dx Gastrointestinal Panels.


Respiratory and gastrointestinal infections affect millions of patients worldwide each year and place a significant burden on healthcare systems. Syndromic testing helps clinicians identify the cause of infection in patients with similar symptoms, supporting appropriate treatment and infection control decisions. QIAGEN’s QIAstat-Dx portfolio is part of the company’s broader Sample to Insight offering, which integrates sample preparation, molecular testing and data interpretation into streamlined diagnostic workflows.


The QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide since launch as of the end of 2025.


To learn more, visit https://www.qiagen.com/applications/syndromic-testing.


About QIAGEN


QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.


Forward-Looking Statement


Certain statements contained in this release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.


Source: QIAGEN N.V.


Category: Infectious Diseases

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310647622/en/
QIAGEN contacts:

Public Relations

e-mail: pr@QIAGEN.com


Investor Relations

e-mail: ir@QIAGEN.com


Original: QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

QIAGEN präsentiert sein Hochdurchsatz-Automationssystem QIAsprint Connect für Labore weltweit auf der SLAS 2026February 3, 2026 4:05 PM
Business Wire

QIAsprint Connect markiert den Einstieg in die Hochdurchsatz-Probenverarbeitung und ermöglicht es Laboren, ihre Workflows mit flexiblen Protokollen, kompaktem Design und auf Nachhaltigkeit ausgelegten Funktionen zu skalieren




QIAGEN zeigt zudem neue Automationssysteme: QIAsymphony Connect für klinische Anwendungen sowie QIAmini für die einfache Probenverarbeitung mit geringem Durchsatz



QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die erste öffentliche Präsentation von QIAsprint Connect auf der SLAS 2026 in Boston angekündigt. Damit steigt QIAGEN in den Markt für hochdurchsatzfähige Tischgeräte für die automatisierte Probenverarbeitung in Forschungslaboren ein.


QIAsprint Connect wurde entwickelt, um Laboren eine effiziente Verarbeitung großer Probenmengen zu ermöglichen – bei gleichzeitig hoher Protokollkontrolle und reduziertem ökologischem Fußabdruck. Das kompakte System verarbeitet bis zu 192 Proben pro Durchlauf und bietet anpassbare Workflows mit einer intuitiven Benutzeroberfläche sowie einem modularen Kit-Design. Auf Nachhaltigkeit ausgelegte Verbrauchsmaterialien reduzieren den Einsatz von Kunststoff und Verpackungsabfall und liefern zugleich eine hohe Leistungsfähigkeit.


Neben QIAsprint Connect wird QIAGEN QIAsymphony Connect vorstellen, eine neue Plattform für die hochergiebige DNA- und RNA-Extraktion in klinischen Laboren, sowie QIAmini, ein kompaktes Automationssystem für Labore mit geringem Durchsatz, die einen einfachen Einstieg in die automatisierte Probenvorbereitung suchen. Gemeinsam unterstreichen diese Systeme einmal mehr QIAGENs Engagement, Labore weltweit mit skalierbaren Automationslösungen zu unterstützen – von niedrigem bis hin zu extrem hohem Durchsatz.


„Labore mit hohem Durchsatz stehen unter ständigem Druck, immer mehr Proben zu verarbeiten, ohne dabei Kompromisse bei Flexibilität, Zuverlässigkeit oder Nachhaltigkeit einzugehen“, sagte Nitin Sood, Senior Vice President und Head of Product Portfolio & Innovation bei QIAGEN. „QIAsprint Connect wurde entwickelt, um Laboren genau dabei zu helfen, und spiegelt die Strategie von QIAGEN wider, die Automatisierung über alle Durchsatzanforderungen hinweg auszubauen. Ein wesentlicher Vorteil ist das neue Sortiment an QIAsprint Verbrauchsmaterialien, die eine hohe Leistungsfähigkeit über verschiedene Anwendungen hinweg ermöglichen und zugleich auf umweltfreundliche Verpackungen und Ressourceneffizienz setzen. Diese Produktneuheit ergänzt die Markeinführungen von QIAsymphony Connect und QIAmini und stärkt unser Angebot für den entscheidenden Startpunkt im Labor-Workflow.“


QIAsprint Connect: Skalierung des Durchsatzes bei der Probenvorbereitung


QIAsprint Connect kombiniert hohe Durchsatzkapazität, flexible Workflows und ein auf Nachhaltigkeit ausgerichtetes Design, um anspruchsvolle Forschungsanwendungen zu unterstützen:



Hochdurchsatz-Effizienz: Verarbeitung von bis zu 192 Proben pro Durchlauf bei minimalem manuellem Aufwand.



Flexible Workflow-Gestaltung: Unterstützung von QIAGEN-geprüften und vollständig anpassbaren Protokollen mittels Touch-Oberfläche und modularer Chemie.



Auf Nachhaltigkeit ausgelegte Verbrauchsmaterialien: Reduzierung des Kunststoffverbrauchs um bis zu 50% sowie Verringerung des Verpackungsvolumens um 40%.



Kompaktes Design für den Labortisch: Hohe Durchsatzleistung in einem platzsparenden Format für bestehende Laborumgebungen.



Konnektivität und Unterstützung regulatorischer Anforderungen: Unterstützung moderner Anforderungen an Datenintegrität und Cybersicherheit, einschließlich 21 CFR Part 11-Konformität.



QIAsprint Connect erweitert QIAGENs Automationsportfolio für Forschungslabore und ergänzt die bestehenden Plattformen im Bereich Automation.


QIAsprint Connect live auf der SLAS 2026 erleben


QIAGEN wird QIAsprint Connect erstmals live auf der SLAS 2026 in Boston am 9. Februar um 14:30 Uhr EST vorstellen.


Am QIAGEN Messestand werden zudem zwei weitere automatisierte Extraktionssysteme präsentiert, deren Markteinführung noch in diesem Jahr geplant ist. Damit unterstreicht das Unternehmen die Breite seines Automationsportfolios für unterschiedliche Durchsatzanforderungen:



QIAsymphony Connect: Die nächste Generation von QIAGENs automatisierter Probenvorbereitungsplattform für die hochergiebige DNA- und RNA-Isolierung in klinischen Anwendungen – mit vollständigem Probentracking und standardisierten Workflows.



QIAmini: Eine kompakte Tischautomationslösung für die vollautomatisierte Probenvorbereitung mit minimalem manuellen Aufwand, die Laboren mit geringem Durchsatz einen benutzerfreundlichen und leichten Einstieg in die Automatisierung bietet.



Weitere Informationen zu QIAGENs Aktivitäten auf der SLAS 2026 finden Sie unter www.qiagen.com/SLAS2026.


Über QIAGEN


QIAGEN N.V., eine niederländische Holdinggesellschaft, ist ein weltweit führender Anbieter von Sample-to-Insight-Lösungen, mit denen Kundinnen und Kunden molekulare Informationen aus biologischen Proben extrahieren und analysieren können, die die Bausteine des Lebens enthalten. Unsere Probentechnologien isolieren und verarbeiten DNA, RNA und Proteine aus Blut, Gewebe und anderen Stoffen. Testtechnologien bereiten diese Biomoleküle auf die Analyse vor, während Bioinformatik-Lösungen die Interpretation komplexer Daten unterstützten, um verwertbare Erkenntnisse zu gewinnen. Automationslösungen integrieren diese Schritte in optimierte, kosteneffiziente Workflows. QIAGEN bedient weltweit mehr als 500.000 Kunden in den Bereichen Life Sciences (akademische Forschung, pharmazeutische F&E und industrielle Anwendungen wie Forensik) und Molekulare Diagnostik (klinische Gesundheitsversorgung). Zum 31. Dezember 2025 beschäftigte QIAGEN rund 5.700 Mitarbeiterinnen und Mitarbeiter an über 35 Standorten. Weitere Informationen über QIAGEN finden Sie unter www.qiagen.com.


Forward-Looking Statement


Einige der Angaben in dieser Pressemitteilung können im Sinne von Section 27A des U.S. Securities Act (US-Wertpapiergesetz) von 1933 in ergänzter Fassung und Section 21E des U.S. Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zukunftsgerichtete Aussagen („forward-looking statements") gelten. Diese Aussagen inklusive solcher über QIAGENs Produkte, den Zeitplan für Entwicklungen, Marketing und/oder regulatorische Genehmigungen, finanzielle und operative Prognosen, Wachstumsstrategien, Kollaborationen und operative Ergebnisse, wie der zu erwartende bereinigte Nettoumsatz und der bereinigte verwässerte Gewinn je Aktie, basieren auf derzeitigen Erwartungen und Annahmen. Diese sind jedoch mit Unsicherheiten und Risiken verbunden. Dazu zählen unter anderem: Risiken im Zusammenhang mit Herausforderungen bei der Steuerung von Wachstum und internationalen Geschäftsaktivitäten (einschließlich Auswirkungen von Währungsschwankungen, Zöllen, Steuergesetzen, regulatorischen Prozessen sowie Abhängigkeiten in der Logistik und Lieferkette); Schwankungen der Betriebsergebnisse und der kommerziellen Entwicklung von Produkten für Kunden in den Bereichen Life Sciences und der klinischen Gesundheitsversorgung, Veränderungen in den Beziehungen zu Kunden, Lieferanten oder strategischen Partnern, das Wettbewerbsumfeld und schneller technologischer Wandel sowie Schwankungen in der Nachfrage nach QIAGEN Produkten (aufgrund von Faktoren wie Wirtschaftslage, Kundenbudgets und Finanzierungszyklen), das Erlangen und die Aufrechterhaltung von Produktzulassungen sowie Herausforderungen bei der Integration von QIAGENs Produkten in Fertigungsprozesse und der Fertigung im großen Maßstab. Weitere Risiken sind die Marktakzeptanz neuer Produkte, die Integration von Akquisitionen, staatliche Maßnahmen, globale oder regionale wirtschaftliche Entwicklungen, Naturkatastrophen, politische Krisen oder Krisen im Bereich der öffentlichen Gesundheit oder sonstige Ereignisse „höherer Gewalt“. Es besteht außerdem keine Garantie, dass der erwartete Nutzen aus Restrukturierungsprogrammen und Akquisitionen wie erwartet eintritt. Eine ausführlichere Erörterung der Risiken und Unsicherheiten finden Sie im Abschnitt „Risikofaktoren“ in unserem aktuellen Annual Report Form 20-F und anderen Berichten, die bei der US-Börsenaufsichtsbehörde (U.S. Securities and Exchange Commission) eingereicht oder dieser zur Verfügung gestellt wurden.


Source: QIAGEN N.V.

Category: Life Sciences

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260203978830/de/
Public Relations

E-Mail: pr@QIAGEN.com


Investor Relations

E-Mail: ir@QIAGEN.com


Original: QIAGEN präsentiert sein Hochdurchsatz-Automationssystem QIAsprint Connect für Labore weltweit auf der SLAS 2026

QGEN under $50

It's an SBD STOCK. :) 100 HERE WE COME.

Is there anybody OUT THERE? :)

Great company progress. This stock will see the light. :)

Added some yesterday. Could be big. :)

Ellume just got a $230 million dollar contract to ramp up production - LIVE CDC Press Conference!

$QGEN - QIAGEN (NYSE: QGEN) is super strong and is steadily getting the attention of institutional buyers !

Look for her to break 52 week high very soon.

QGEN News

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.

QGEN Full PR

QGEN News

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.

QGEN Full PR

News: $QGEN What Happens Next for Illumina and Pacific Biosciences?

When first learning of a proposed acquisition, it can be easy to subconsciously slip over the word "proposed" as linguistic fodder. But although many acquisitions earn regulatory approval relatively quickly, some trip up enough alarm bells among trade authorities to significantly slow closing or...

Got this from QGEN - What Happens Next for Illumina and Pacific Biosciences?

News: $QGEN QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of inter...

Read the whole news QGEN - QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

News: $QGEN QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives

VENLO, THE NETHERLANDS / ACCESSWIRE / November 15, 2019 / QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the ac...

Got this from QGEN - QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives

News: $QGEN QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and ou...

Find out more QGEN - QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives

What "pharmaceutical company" is QGEN and HTBM doing the work for under this SOW?

http://ih.advfn.com/p.php?pid=nmona&article=75007037

"Effective June 14, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) entered into a statement of work (the “SOW”) with QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V. The SOW was entered into pursuant to the Company’s Master Assay Development, Commercialization and Manufacturing Agreement (the “Master Agreement”) with QIAGEN, and addresses development activities expected to be conducted by the Company and QIAGEN in connection with the initial phase of a sponsor project agreement entered into between QIAGEN and a pharmaceutical company (“Initial Phase”).

Under the SOW, the Company and QIAGEN are expected to perform development work for the Initial Phase of what is expected to become a multi-stage project leading to the potential development and commercialization of a next generation sequencing-based companion diagnostic assay. The development work is expected to support one of the pharmaceutical company’s therapeutic development and commercialization programs. QIAGEN will pay the Company low single digit millions of dollars for the Initial Phase development work performed under the SOW, and the Company and QIAGEN will also share in any net profits (as determined under the Master Agreement) generated by the Initial Phase...."

$QGEN DD Notes ~ http://www.ddnotesmaker.com/QGEN

bullish
symmetrical triangle breakout

$QGEN recent news/filings

## source: finance.yahoo.com

Mon, 22 Dec 2014 15:34:25 GMT ~ QIAGEN Marseille receives management offer for certain company assets

[at noodls] - Monday December 22, 2014 The members of QIAGEN Marseille executive committee have offered to take over all non IP-related assets, including all of the work force, for the formation of a new company, HalioDx ...

read full: http://www.noodls.com/view/8ECB8697C6C35E5EBFC8CF877CCC7333D7E4A46B
*********************************************************

Tue, 16 Dec 2014 11:13:17 GMT ~ UMS United Medical Systems International AG: UMS United Medical Systems International AG, Hamburg launches buyback offer for up to 475,766 shares

[at noodls] - Nachholbedarf bei IR-TV-Formaten Drei Viertel der großen deutschen Konzerne nutzen redaktionelle TV-Formate für Pressearbeit, Werbung oder Personalgewinnung. Im Bereich Investor Relations setzt dagegen ...

read full: http://www.noodls.com/view/A102A32C42585BAAE34C20924B25353429A7DAD3
*********************************************************

Tue, 09 Dec 2014 15:56:40 GMT ~ Press Release: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme

[at noodls] - Nachholbedarf bei IR-TV-Formaten Drei Viertel der großen deutschen Konzerne nutzen redaktionelle TV-Formate für Pressearbeit, Werbung oder Personalgewinnung. Im Bereich Investor Relations setzt dagegen ...

read full: http://www.noodls.com/view/7632BDA978A3398E1FCC4979E6F372A1118F5B06
*********************************************************

Thu, 04 Dec 2014 21:00:00 GMT ~ QIAGEN to Distribute altona Diagnostic's RealStar® Ebolavirus RT-PCR Kit 1.0, Recently Authorized by the FDA for Emergency Use

[PR Newswire] - HILDEN, Germany and GERMANTOWN, Maryland, December 4, 2014 /PRNewswire/ -- New molecular diagnostic test detects but does not differentiate all existing strains of Ebola virus Partnership with altona ...

read full: http://finance.yahoo.com/news/qiagen-distribute-altona-diagnostics-realstar-210000954.html
*********************************************************

Thu, 13 Nov 2014 18:20:02 GMT ~ Qiagen Partners with Novartis for Companion Diagnostics


read full: http://finance.yahoo.com/news/qiagen-partners-novartis-companion-diagnostics-182002501.html
*********************************************************


$QGEN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$QGEN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/QGEN/company-info
Ticker: $QGEN
OTC Market Place: Not Available
CIK code: 0001015820
Company name: QIAGEN N.V.
Company website: http://www.qiagen.com
Incorporated In: Netherlands


$QGEN share structure

## source: otcmarkets.com

Market Value: $5,522,145,686 a/o Dec 26, 2014
Shares Outstanding: 233,890,118 a/o Dec 31, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$QGEN extra dd links

Company name: QIAGEN N.V.
Company website: http://www.qiagen.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=QGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=QGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=QGEN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/news - http://finance.yahoo.com/q/h?s=QGEN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/QGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=QGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/QGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=QIAGEN+N.V.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=QIAGEN+N.V.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=QIAGEN+N.V.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.qiagen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.qiagen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.qiagen.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/QGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001015820&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=QGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=QGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=QGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=QGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=QGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=QGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=QGEN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/QGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=QGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/QGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=QGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/QGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/QGEN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/QGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/QGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/QGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=QGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=QGEN



$QGEN DD Notes ~ http://www.ddnotesmaker.com/QGEN

7:16AM Qiagen announces two agreements adding 'promising' new biomarkers involving glioblastoma, lymphoma and other cancers to co's expanding portfolio of potential companion diagnostics (QGEN) 18.92 : Co announced two agreements adding promising new biomarkers involving glioblastoma, lymphoma and other cancers to QIAGEN's expanding portfolio of potential companion diagnostics that is being developed to help doctors use a patient's genomic information to guide treatment decisions. In the glioblastoma project, co has entered into an exclusive worldwide licensing option on FGFR-TACC fusion genes with Columbia University in New York. QIAGEN intends to develop this biomarker into a diagnostic test for routine use in diagnostic workups, which may enable doctors to identify glioblastoma patients who could benefit from targeted treatments now under development. Co has also entered into an exclusive license option with the BC Cancer Agency, based in Vancouver, British Columbia, Canada, for the EZH2 Y641 mutation biomarker that could serve as a companion diagnostic test for routine selection of patients who could benefit from EZH2 targeted therapies that are currently under development by major pharmaceutical companies.

QIAGEN (QGEN) and Bayer (BAYRY) HealthCare signed a collaboration agreement aimed at advancing both cos' positions in personalized medicine. The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare.

QGEN downgraded to Market Perform from Outperform at Leerink - Yahoo! Finance http://finance.yahoo.com/news/qiagen-downgraded-market-perform-outperform-102431222.html via @YahooFinance

QIAGEN N.V. (QGEN) 1Q 2012 Earnings Call April 24, 2012 9:30 AM ET

Operator

Ladies and gentlemen, thank you for standing by. Welcome to QIAGEN N.V. investor and analyst conference call on the Q1 results 2012. (Operator instructions) I would not like to turn the conference over to Albert Fleury, Director Investor Relations and Corporate Finance NA. Please go ahead, sir.

Albert Fleury

Thank you. Good afternoon and good morning to you in the U.S. and welcome to the QIAGEN conference call to discuss our latest quarterly results. Joining me on the call this morning are Peer Schatz, Chief Executive Officer, Roland Sackers, Chief Financial Officer, and John Gilardi, Vice President, Corporate Communications and Investor Relations. A copy of this announcement and the presentation for this conference can be downloaded from the Investor Relation’s section of our home page at www.qiagen.com.

Before I turn the call over to Peer, please keep in mind that the following discussion and responses to your questions reflect management’s view as of today, April 26, 2012. As we share information to help you better understand our business, we will make statements and provide responses that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. These involve certain risks and uncertainties that could cause QIAGEN’s actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For a complete description of the risks and uncertainties, please refer to our Form 20-F filed with the U.S. Securities and Exchange Commission.

At this time I’d like to now hand the call over to Peer.

Peer Schatz

Thank you, Al. Good morning to all joining us from the United States and good afternoon to all joining from Europe. I’d like to welcome you all into our conference call and the opportunity to discuss our results for the first quarter of 2012. As you saw in our release last night, we are pleased with our start into 2012 and improving demand for our products across all customer classes and regions. And sales were $296 million representing a 13% increase at constant exchange rates.

Adjusted operating income rose 14% to approximately $80 million and adjusted diluted earnings per share rose to $0.23 per share. These results led by double-digit growth in all regions and also contributions from all customer classes were ahead of our targets. What were the reasons? Demand for our product among customers and Pharma Applied Testing and Academia improved better over the first quarter of 2011, a period that was adversely affected by the disasters in Japan as well as unrest in Northern Africa.

We also saw solid gains among our growth drivers in molecular diagnostics. These include companion diagnostics for personalized health care. These areas are contributing more than $75 million in sales across QIAGEN and growing rapidly. We’re also seeing solid growth for our disease profiling tests. Growth in this area is further underpinned by the success of QIAsymphony. HPV sales were flat in the quarter. As we have said, HPV is not expected to be a growth driver in 2012, however, remains a solid foundation for our expansion in molecular diagnostics into the growth driver areas that include personalized health care and profiling.

In terms of the 13% constant exchange sales growth, about 7% percentage points came from the Celestus and Ipsogen acquisitions completed in the third quarter of 2011. The rest of business delivered 6 percentage points, so we’re seeing signs of improvement over 2011. A key driver has been the progress we have been making on our strategic initiatives to drive platform success, to add content, to broaden our geographic presence and to grow efficiently and effectively.

Important developments in the first quarter of 2012 included the first regulatory clearance of a QIAsymphony component in the United States, the Roto-Gene Q real-time PCR cycler and in China we received approval for the second of three components, in this case, the QIAsymphony SP module.

In terms of adding content, we are preparing for the U.S. approval of the KRAS biomarket tests. FDA decisions are expected during 2012.

And we are improving our efficiency and effectiveness. The efficiency program launched in late 2011 is making good progress and we are now implementing projects that are freeing up resources to reinvest. Also in our press release we announced some organizational leadership changes. Effective July 1, we are creating two business areas; Molecular Diagnostics and Life Sciences. I will touch on this topic later.

Moving to Slide 5, I wanted to show you how we view the various contributors to our performance; Molecular Diagnostics which represented 47% of QIAGEN sales rose 21% on the constant exchange rate basis. We are to invest even more in our rapid growth drivers. These include personalized health care, profiling and QuantiFERON-TB test. These and other products together delivered 37% constant exchange rate growth and represented 29% of our sales.

As I mentioned earlier, we are seeking to maximize the value of our HPV franchise. We had flat sales in the first quarter of 2012, both in the U.S. and globally and this product now represents 18% of net sales globally. In the United States the contribution is fallen to 14% of sales in the first quarter of 2012 compared to 16% in the first quarter of 2011.

I want to reaffirm a few statements. First, no HPV competitor has come out with a better product, neither in terms of clinical data nor in terms of automation. Most, in fact, have significantly inferior clinical profiles. Second, HPV is valuable in providing critical mass in building relations with customers. We are determined to maintain our HPV leadership and are successful in doing so, as we have a very strong, competitive offering. Third, we believe our rapid growth drivers should more than outweigh any concerns in 2012 about lower HPV sales in the United States.

Turning to the life sciences, which involves the Academia, Pharma, and Applied Testing customer classes, here we are focusing on new opportunities. You can see that Applied Testing and Pharma both delivered very robust, double digit growth in the first quarter of the year. Academia was also a contributor, amid improving trends albeit with growth at a much slower pace than in the past. We are still seeing uncertainties about funding in Academia going into the second half of the year and in 2013, both in the U.S. and Europe.

Overall this performance gives us confidence about accelerating full year growth in 2012 over 2011. As for our full year guidance, we see it as a balanced, taking into account the opportunities and risks we see. What we can say at this time is that we are increasingly confidence of achieving the guidance and we will review it accordingly as the year progresses.

I would like to hand over to Roland for a review of our financial performance. Roland?

Roland Sackers

Thank you, Peer and good afternoon to everyone in Europe. Good morning to those joining from the U.S. As you heard from Peer, we have started the year with good momentum and are committed to accelerating our full year growth in 2012, over our results in 2011.

Today I will briefly talk about our performance in the first quarter, before providing you with an update on our outlook on the rest of the year.

On slide 6, you'll see our key results for the quarter. Net sales grew rose 13% at constant exchange rates to approximately US$296 million. Consumables sales were up 14% using constant exchange rates, while Instruments rose at a slower 5% pace, using constant exchange rates, in the period.

Adjusted gross profit rose 10% to approximate US$210 million. The adjusted gross profit margin was 71% for the first quarter of the year, down slightly from 72% in the first quarter of 2011.

As you may recall, the adjusted gross profit margin in the fourth quarter of 2011, was 69%. We saw this as a normal way to slip below 70%. That census was due to specific factors in that period, namely the gross margin on companion diagnostic co-development payments that were booked as revenues. As you can see, we've returned to a level above 70%, and are on track to meet our full year target of an adjusted cost margin of between 70% and 71%.

I also want to highlight that (inaudible) adjusted gross profit margin while driving rapid of QuantiFERON-TB test. When it is manufactured by a third party it has gross margin below the (inaudible) consumable average. Adjusted operating income was 14% to approximately US$80 million from the first quarter of 2011 and the adjusted operating margin remains steady at 27% of net sales.

As a percentage of net sales, higher manufacturing and sales costs were essentially upset by lower spending on R&D, marketing and administration. Adjusted diluted earnings per share were $0.023 in the first quarter, up from $0.21 in the same period of 2011. (inaudible) despite a higher adjusted tax rate. First quarter of 2012 compared to 26% in the same period of 2011.

I also want to note there the difference between the reported tax rate, which was 14%, and the adjusted tax rate. The difference was due mainly to a much higher tax rate on the adjustments, since these were mainly in high tax jurisdictions. In summary, the third quarter for QIAGEN was a solid start to the year.

I’m now on Slide 7. For the quarter we delivered double-digit growth in all regions and we were particularly pleased with the broad business expansion in the Americas, namely the U.S., Canada and Brazil. The Americas, which account for 47% of net sales grew 15% using constant exchange rates. Placement QIAsymphony tests across all customer classes, as well as contributions from the QuantiFERON-TB test underpinned this growth. In the U.S., as noted by peer, HPV were stable in the first quarter. The Europe, Middle East and Africa region, which account for 34% of net sales, grew 12% using constant exchange rates. Spain and some other areas of southern Europe remain challenging.

However, our exposure in this region is quite small and other areas of Europe are doing better, such as Germany, France and the Nordic region and we also saw improvement this year (inaudible) in Italy. The Asia-Pacific and Japan region accounted for about 18% of net sales and grew 14% using constant exchange rates. Growth is mainly lead by contributions from Molecular Diagnostics.

We also experienced important growth contributions, however, from Pharma and Academia. The key markets remain China and Japan. We continue to be pleased with some momentum of QuantiFERON-TB test in this region, as well.

Moving to Slide 8, here is an overview of our financial position at the end of the first quarter. We continue to have a healthy balance sheet and solid financial position. One that we can use to strengthen our operations. We continue to review various M&A opportunities along our three strategic areas of Novell Technologies, adding content to our portfolio and geographic expansion.

As of March 31 group liquidity was approximately US$275 million which compares to approximately US$276 million as of December 31, 2011. Our equity ratio stood at 69% compared to 68% at the end of 2011. Our leverage has decreased slightly to approximately 0.8 times net debt to EBITDA from about 0.9 at the end of 2011. As for free cash flow, we had said in the Q1 results would be grossly affected mainly due to the restructuring payments for the efficiency program launched late in the fourth quarter of 2011 and this was the case.

Although reported net income was essentially steady at US$28 million, we experienced a growth development in other non-cash components, in income and working capital which led to negative free cash flow for the first quarter. Among reasons for the change in working capital which amounted to US$45.5 million in the first quarter of 2012 compared to US$16 million in the prior year quarter where cash restructuring payments of approximately US$20 million. Also in the first quarter of 2012 we experienced an unusually low level of accounts payable compared to the first quarter in 2011 and we also made some tax payments for both 2011 and 2012 in the first quarter of this year.

Those were among the main reasons for the performance of free cash flow and, again, they expect improvement during the course of 2012. I would now like to hand it back to Peer for a strategy update.

Peer Schatz

Thank you, Roland. I am now on Slide 6 to provide you an overview of our strategic initiatives and goals set for 2012. We are well on track to achieve our number one goal which is to have more than 200 new QIAsymphony systems by the end of 2012. This builds on the more than 550 systems in place at the end of 2011. We are in the early years of a decade long product cycle, and we expect the rollout to be successful based on QIAsymphony's versatility in terms of sample processing bandwidth, as well as flexibility to prepare and process assays. In terms of adding content, we are preparing important regulatory submissions that include a Therascreen EGFR by a market test in the U.S., and decisions on our two Therascreen KRAS submissions could be expected in 2012. Discussions with the FDA remain positive.

As we broaden our geographic presence, we are reviewing options to expand in new markets in Eastern Europe, Asia, and Latin America. And in terms of growing efficiently and effectively, we have completed the streamlining of our organization that began in late 2011. We are now working to free up additional resources that can be reallocated to further initiatives through various operational projects. These actions and reinvesting the savings will help improve our growth profile in 2013 and beyond, and also provide positive impulses to our adjusted operating margin.

Turning to slide 10, I want to give you an update on the QIAsymphony automation system. We see QIAsymphony as a family of components that offers customers the industry's first fully integrated system from sample preparation to clinical results. First, we recently received U.S. regulatory clearance for the Rotor-Gene Q, and we are working on development plans to gain clearance for QIAsymphony SP and AS modules. Gaining this first clearance is critical to expanding our test menu in the United States, since future assay submissions will be based on this platform and can now leverage the work that lead to the submission of the first module. We are continuing to see strong growth in demand for consumables. Every placement creates an opportunity for annual consumable sales, or so called pull through, of anywhere between $30,000 to $300,000. And we continue to view QIAsymphony as a very valuable, very long term growth driver.

Turning to slide 11, here is an overview of the submissions for which we have recently received regulatory approvals, as well as completed in 2011 and what we have planned for 2012. We are looking forward to completing a number of important regulatory submissions to expand the menus of our system. Top priority is the U.S. submission of the Therascreen EGFR assay. The first submission for this assay is planned as a companion diagnostic for (inaudible), the lung cancer drug in development with Boehringer-Ingelheim. This will build on the 2011 submissions of KRAS and also the 2011 approvals of the KRAS and EGFR assays in Japan, one of the largest markets for companion diagnostics. With over 15 projects, we have the industry's deepest pipeline of partnered molecular, companion diagnostics that will build on these submissions.

Moving onto global regulatory affairs, we presently have over 50 ongoing R&D projects, which include regulatory submissions or registrations. As you can see, this represents a growing global portfolio of regulated products, and we are now moving to build up the testing menu in the United States to mirror what we have in other regions.

Turning to Slide 12, I wanted to address some of the questions we have been getting about the market potential for QuantiFERON-TB. We believe this product, which we acquired with Celestus in August 2011, is being underappreciated. 2011 pro forma sales were about $55 million and the growth rate continues at more than 20% constant exchange rate. We see long-term growth potential for QuantiFERON-TB in the United States worldwide. We're at a very low market penetration level, still.

As we've been saying, we see the latent TB testing market, which is a market in the developed world, as about 50 million tests and one valued at about $1 billion. Alone in the United States, our current estimate is that the market is about 15 million tests, and distributed among these segments as you can see here on the slide. Apart from the more than 100-year-old skin test, there is no other test on the market with any significant sales nor is there any in the pipeline.

Areas in blue are the primary targets at this time; however we are building up sales and marketing organizations to move much more aggressively into the other segments, especially immuno-compromised patients. So you'll be hearing a lot more about QuantiFERON-TB in the future and seeing it become a key contributor to our growth.

Turning to Slide 13, QIAGEN has established a leadership position in personalized health care, one anchored on various revenue streams. Sale of commercial biomarker kits for use as companion diagnostics, but also in clinical trials involving patients. Milestone payments from co-development projects. We have a robust portfolio of projects underway with many leading Pharma companies, and we are looking to add new projects in 2012. And we also have revenues from associated products, such as sample technologies, asset technologies, instruments, gene-globe molectro-pathway analysis tools, etc. We have created a business with sales of about $75 million in 2011, growing it more than 20% overall with contract development services as a base in strong growth, very strong growth, in Therascreen branded assays and related products.

We expect ongoing, strong growth in 2012, especially as we expand the commercial sales of our tests in Europe, as well as build up our presence in Japan after the approval of Therascreen KRAS and EGFR biomarker tests during 2011 in that region. And most important, we are preparing for the commercial launch of our Therascreen KRAS test as a companion diagnostic for Urbatox and Vectibix in the United States. We wanted to outline the U.S. market potential for KRAS and colorectal cancer only, which will be the indication for this test.

Based on the breakthrough data presented at ASCO a few years ago, we currently estimate that about 75,000 KRAS tests are being performed annually in this area, for this indication, in the United States. We currently sell about 20,000 PCR based KRAS tests in the United States while the rest of this market is estimated to involve laboratory developed tests. Our first priority is to convert laboratory developed tests to our tests. We are very encouraged by the response and acknowledgement by these labs about to benefit from switching to an FDA approved test.

Beyond these tests we will be working with our Pharma partners to drive penetration to an even higher level. Based on an estimated price of about $200 per reportable test, KRAS and colorectal cancer will be an attractive growth driver for QIAGEN. And that is just the start. We are working to add a theraScreen KRAS test for lung cancer and beyond KRAS the next submission will involve ETFR also for lung cancer already in 2012. These opportunities represent potential markets and show you why we are optimistic about maintaining a rapid growth pace in the future.

I'm now on Slide 14. As you know we announced a project in November to grow more efficiently and more effectively. We are enhancing productivity and have a goal to free up about $50 million of pre-tax resources for reallocation to strategic initiatives. In the first phase we have completed the streamlining of our organization and the workforce was reduced by approximately 10%. This is a net number since we are going to redeploy resources into areas that can provide faster top line growth. Teams are now working on initiatives across the organization. Key areas include focusing our R&D portfolio on growth areas across all customer classes. This obviously also includes personalized health care as well as QIAsymphony.

We're also going to optimize capacity utilization and are reviewing our site network. The project is moving quickly and we booked approximately $11 million of restructuring charges in the first quarter. Further charges are likely to be taken during 2012 and we had said that these could total up to about $20 million for the full year. And as we mentioned earlier, the payback on these investments will become evident in 2013.

Moving to Slide 15, as you saw in our announcement last night we have made important changes to QIAGEN's organizational structure at the top level, as well. These changes are designed to capture new opportunities and better address customer needs. Most importantly, as of July 1, two new business areas are being created to intensify the focus on our customers. They are Molecular Diagnostics and Life Sciences, whereby Life Sciences comprises Academia, Pharma and Applied Testing.

As I mentioned earlier, Dr. Helga Lubenow is appointed Senior Vice President, Molecular Diagnostics and Dr. Dietrich Hauffe is appointed Senior Vice President, Life Sciences. Both will become members of the executive committee. Joachim Schorr, who had been Senior Vice President of Research and Development and a Managing Director, has decided to leave QIAGEN and pursue personal projects, but he has been retained as a consultant. Michael Collasius, former Senior Vice President of Automation, will take on a new role with responsibility for project management and business process excellence reporting to me. All other members of the EC remain in their previous roles.

We believe these changes will promote faster decision making, customer-centric decision making and our goal is to deliver targeted innovation at a faster pace through better connections with our customers. This is the appropriate time in the development of QIAGEN to make this transition into business areas and regions. It will help to better prioritize and align our R&D and commercial activities, all with the goal of driving innovation and growth at a faster pace. I would now like to hand back to Roland.

Roland Sackers

Thank you, Peer. Now on Slide 16. I would like to give you an outlook for the second quarter and for the year 2012 and assumptions for adjustments to operating income. As you mentioned earlier, we have reaffirmed our full year outlook for 2012. We also provided targets for the second quarter including our expectations for a net sales growth of approximately 11% to 12% at constant exchange rates.

As was the case this first quarter, we expect some headwind as reported to us due to year-on-year foreign currency movements. Adjusted EPS for the second quarter is expected to be about $0.24 per share. This reflects the usual trend of relatively higher cost at the start of the year, but then an improving margin profile as the year progresses.

For the full year, we continue to expect total sales growth of about 6% to 8% using constant exchange rates based off a mix of contributions from Celestus and Ipsogen acquisitions as well as from the result of our business. These estimates, as usual, do not take into account any acquisitions that could be done in 2012.

Based on average foreign exchange rates so far in 2012, our reported full year results will continue to show some pressure from currency movements. We currently expect currency (inaudible) of about two to three percent points. The actual reported results would then be lower than the total constant exchange rate, which adjusted earnings per share for the full year as expected to be between $1.03 and $1.05 per share. This is based on approximately 239,000,000 fully diluted shares outstanding.

We also have here on this slide the assumptions for adjustments to operating income for the second quarter of 2012 and for the full year. EBITDA, the best compensation of about US$21 million to US$22 million remains the expectation. About US$110 million is spent for the amortization of acquired intellectual property. About US$30 million is planned for business integration, acquisition and restructuring this includes about $20 million for the efficiency project, of which $11 million was taken in the first quarter. Also included here is about $8 million of acquisition-related cost for (inaudible) and their integration. The adjusted tax rate is expected to still be about 21% and 23%, which compares to 23% in 2011.

With that, I would now like to hand back to Peer.

Peer Schatz

Yeah, thank you, Roland. I'm not on Slide 17 for the summary before we move into Q&A. We started 2012 with an intensified focus on accelerating our full-year growth rates, and we are increasingly confident of achieving our full-year targets. Critical to achieving this goal is making further progress on our strategic initiatives. We are creating a foundation for future growth, lead by the ongoing strong rollout of QIAsymphony, and we are stepping up our initiatives to add content to our portfolio, both through internal R&D, as well as targeted acquisitions and licensing. We are going to continue expanding our geographic presence in high growth markets, which are increasing their contributions to our results, and we will intensify our actions to improve efficiency and effectiveness through the project we launched in 2011.

In closing, we have shown with our results in the first quarter that QIAGEN is improving its performance and is ready to accelerate growth in 2012 compared to 2011. With that, I'd like to hand back to Al to open up the Q&A session. Thank you.

Albert Fleury

Thank you, Peer. We now look forward to taking your questions. Also please note to ensure we can accommodate as many people as possible, please limit yourselves to only one question, and if necessary, one follow up. We're implementing a new policy to mute your line after you ask one question and then the follow up. However, you are welcome to rejoin the cue to ask another question if time permits. Operator?

This transcript was sent to 87 people who get email alerts on QGEN.

http://seekingalpha.com/article/533791-qiagen-s-ceo-discusses-1q-2012-results-earnings-call-transcript?source=yahoo

HA! ~ $QGEN ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $QGEN ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=QGEN&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=QGEN&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/QGEN?
~ OTC Markets: http://www.otcmarkets.com/stock/QGEN/company-info
~ Google Finance: http://www.google.com/finance?q=QGEN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=QGEN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=QGEN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=QGEN
Finviz: http://finviz.com/quote.ashx?t=QGEN
~ BusyStock: http://busystock.com/i.php?s=QGEN&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=QGEN&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=QGEN
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=QGEN
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=QGEN
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=QGEN
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=QGEN
~ MarketWatch: http://www.marketwatch.com/investing/stock/QGEN/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=QGEN
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=QGEN
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=QGEN&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=QGEN&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=QGEN&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

QIAGEN Reports Fourth Quarter and Full-Year 2011 Results
PR Newswire

VENLO, The Netherlands, January 31, 2012

VENLO, The Netherlands, January 31, 2012 /PRNewswire/ --

Strong performance in fourth quarter of 2011: Net sales increase 17% (+17% CER) to $334.4 million on double-digit growth across all regions; adjusted EPS rises 19% to $0.31
Significant progress on strategic initiatives to drive growth and innovation:
Driving platform success: More than 550 QIAsymphony systems installed by year-end 2011 with a strong pipeline for 2012; QIAensemble Decapper automation unit launched
Adding content: Expanding biomarker portfolio in Personalized Healthcare; products from Cellestis and Ipsogen acquisitions contribute to growth in second half of 2011
Broadening geographic presence: Dynamic expansion in high-growth markets
Growing effectively: Efficiency project launched in late 2011 with pre-tax savings goal of $50 million in 2012, reallocating resources to drive adjusted margin growth in 2013
QIAGEN expects to deliver sales and adjusted earnings growth at a faster pace in 2012
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) has announced results of operations for the fourth quarter and full-year 2011, making significant progress on strategic initiatives to drive growth and innovation.

Net sales in the fourth quarter advanced 17% (+17% at constant exchange rates, or CER) to $334.4 million from the fourth quarter of 2010. Adjusted operating income in the quarter grew 16% to $95.6 million compared to the fourth quarter of 2010 as the adjusted operating income margin was steady at 29% of net sales. Adjusted diluted earnings per share (EPS) rose to $0.31 in the fourth quarter of 2011 from $0.26 in the same quarter of 2010. Results for the fourth quarter of 2011 included a restructuring charge of $75 million for a project announced in November to enhance productivity by streamlining the organization and freeing up resources for reallocation to strategic initiatives.

Full-year 2011 net sales rose 8% (+4% CER) to $1,169.7 million from $1,087.4 million in 2010. Adjusted operating income in 2011 was up 4% to $319.6 million from $308.2 million a year earlier, while adjusted diluted EPS were $0.98 compared to $0.93 in 2010.

"We are pleased with our performance in the fourth quarter of 2011, ending the year with strong growth in all areas of our business. We made significant progress in 2011 on our strategic initiatives, delivering growth at a faster pace in the second half of the year while increasing sales in Molecular Diagnostics, Applied Testing, Pharma and Academia. In particular, we are expanding our leadership in Personalized Healthcare and setting new standards for laboratory automation with the successful QIAsymphony system rollout," said Peer Schatz, Chief Executive Officer of QIAGEN N.V. "With the positive momentum we are experiencing, we expect to accelerate growth to a faster pace in 2012 than in 2011 while taking a conservative view on macroeconomic challenges and on the budget funding environment. As we intensify our focus on growth areas across all of our customer classes, we look forward to building momentum and advancing QIAGEN's position in 2012 as a global leader in molecular technologies."

Fourth quarter 2011 results

Fourth Quarter 2011 Change
In $ millions, except per share
information Q4 2011 Q4 2010 $ CER
Net sales 334.4 286.0 17% 17%
Operating income, adjusted 95.6 82.4 16%
Net income, adjusted 73.6 62.0 19%
EPS, adjusted ($) 0.31 0.26
For information on the adjusted figures, please refer to the
reconciliation table accompanying this release.
Net sales grew 17% to $334.4 million in the fourth quarter of 2011 from $286.0 million in the 2010 quarter. Total sales rose 17% CER, with organic growth contributing 11 percentage points and the contributions of Cellestis (as of August 29) and Ipsogen (as of July 12) providing six percentage points. Currency movements had no net impact on the reported sales growth.

Operating income for the fourth quarter of 2011, which included a restructuring charge of $75 million, amounted to a loss of $19.6 million, compared to income of $50.8 million in the same period of 2010. Adjusted operating income, which excludes one-time items, equity-based compensation and the amortization of intangible assets, rose 16% to $95.6 million from $82.4 million in the fourth quarter of 2010.

Net loss attributable to owners of QIAGEN N.V. was $0.4 million compared to net income of $36.3 million in the fourth quarter of 2010, while adjusted net income attributable to owners of QIAGEN N.V. rose 19% to $73.6 million in the fourth quarter of 2011 from $62.0 million in the year-earlier period.

Diluted EPS in the fourth quarter of 2011 were $0.00 (based on 236.7 million diluted shares) compared to $0.15 in the same period of 2010 (based on 239.4 million diluted shares). Adjusted diluted EPS were $0.31 compared to $0.26 in the same quarter of 2010.

Reconciliations of reported results in accordance with U.S. generally accepted accounting principles (GAAP) to adjusted results are included in the tables accompanying this release.

"We achieved double-digit organic growth in the fourth quarter of 2011, led by especially strong results in Molecular Diagnostics. Strong underlying growth was also further supported by the timing of an HPV tender delivered at the end of the year. Applied Testing delivered a markedly improved performance, and we were pleased with the contributions of Pharma and Academia despite an uncertain funding environment," said Roland Sackers, Chief Financial Officer of QIAGEN N.V. "As we maintain our focus on accelerating sales and adjusted earnings growth rates, our solid financial position provides us with significant flexibility to help improve our performance through targeted acquisitions and R&D investments. The efficiency actions launched in late 2011, which are moving ahead of our initial projections, will further strengthen QIAGEN and provide effective and efficient resource allocations to support our strategic initiatives."

Full-year 2011 results

Full-Year 2011 Change
In $ millions, except per share
information FY 2011 FY 2010 $ CER
Net sales 1,169.7 1,087.4 8% 4%
Operating income, adjusted 319.6 308.2 4%
Net income, adjusted 234.4 222.7 5%
EPS, adjusted ($) 0.98 0.93
For information on the adjusted figures, please refer to the
reconciliation table accompanying this release.
For the full-year 2011, net sales rose 8% to $1,169.7 million compared to $1,087.4 million in 2010. Total sales grew 4% at constant exchange rates, with organic sales and acquisitions each contributing two percentage points. Favorable currency movements added four percentage points in reported sales growth.

Operating income in 2011 was $99.6 million, a 47% decline from $188.5 million in 2010, primarily due to the impact of a restructuring-related charge in the fourth quarter of 2011 as well as one-time charges related to the acquisitions of Cellestis and Ipsogen. Adjusted operating income, which excludes one-time items, equity-based compensation and the amortization of intangible assets, rose 4% to $319.6 million from $308.2 million in 2010.

Net income attributable to owners of QIAGEN N.V. was $96.0 million in 2011, down 33% from $144.3 million in 2010, while adjusted net income attributable to owners of QIAGEN N.V. grew 5% to $234.4 million from $222.7 million in the prior year.

Diluted EPS in 2011 declined to $0.40 (based on 239.1 million diluted shares) compared to $0.60 (based on 240.5 million diluted shares) in 2010, while adjusted diluted EPS rose to $0.98 in 2011 from $0.93 in 2010.

Reconciliations of reported results in accordance with U.S. generally accepted accounting principles (GAAP) to adjusted results are included in the tables accompanying this release.

Business review

Geographic regions

All geographic regions delivered double-digit CER growth in the fourth quarter of 2011, led by Europe / Middle East / Africa (36% of net sales, +22% CER) and driven by the rollout of the QIAsymphony automation system. Results in the Americas (46% of net sales, +16% CER) benefited from double-digit growth in Molecular Diagnostics and Applied Testing. The Asia-Pacific / Japan region (18% of net sales, +18% CER) had growth contributions from Pharma, Molecular Diagnostics and Applied Testing.

Product categories

Consumables and related revenues (85% of net sales, +18% CER) rose at a solid pace in all customer classes in the fourth quarter of 2011. For the full-year 2011, consumables and related revenues rose 5% CER and represented 87% of net sales compared to 2010. Instrument sales (15% of net sales, +11% CER) were supported by targeted initiatives across QIAGEN's broad product portfolio. QIAsymphony placements contributed to growth in cash sales as well as growing pro-rata contributions under multiyear reagent rental agreements implemented since the launch of the full QIAsymphony RGQ system in late 2010. Full-year 2011 instrument sales rose 1% CER compared to 2010 and represented 13% of net sales.

Customer classes

Among the performances in QIAGEN's four customer classes (based on total sales results that include organic growth and acquisitions at CER):

Molecular Diagnostics (Q4 2011: 50% of net sales, +30% CER) delivered a dynamic double-digit expansion. Profiling was led by the global rollout of the QIAsymphony automation platform and increasing use of QIAGEN's extensive and expanding testing portfolio in Europe (in particular in virology, including in HIV, HCV and HBV testing) and other markets outside the U.S. Personalized Healthcare advanced at a rapid double-digit pace on significantly higher companion diagnostic test sales as well as contributions from milestone payments for co-development projects with pharmaceutical companies. In Prevention, global HPV (human papillomavirus) testing sales grew at a double-digit pace, helped by a national HPV tender in the Americas that was delivered in the fourth quarter of 2011, plus growth in other international markets. U.S. HPV sales were stable compared to the fourth quarter of 2010, as a modest improvement in volume offset the pricing effects of multiyear agreements implemented with many customers. Significant contributions from the acquisitions in the second half of 2011 of Cellestis (QuantiFERON-TB Gold test for latent TB) and Ipsogen (blood cancer biomarker and test portfolio) further contributed to total sales growth. Full-year 2011 Molecular Diagnostics sales rose 7% CER and represented 47% of net sales.

Applied Testing (Q4 2011: 7% of net sales, +18% CER) grew on significantly higher instrument sales compared to the fourth quarter of 2010. Consumable product sales improved at a double-digit pace, led by human identification and forensics products and spurred by the introduction of new European standards, as well as contributions from new veterinary testing and food safety products. Full-year 2011 Applied Testing sales rose 1% CER and represented 7% of net sales.

Pharma (Q4 2011: 19% of net sales, +8% CER) showed healthy sales growth for instruments and consumables, led by demand for products used in oncology research as well as the GeneGlobe portfolio of molecular pathway analysis products. Also contributing was ongoing expansion of Certal products used on QIAsymphony for quality control in biopharmaceutical processing. Full-year 2011 Pharma sales rose 4% CER and represented 20% of net sales.

Academia (Q4 2011: 24% of net sales, +3% CER) generated single-digit sales growth in both consumable kits and instruments in the fourth quarter of 2011, benefiting from initiatives in the second half of 2011 to accelerate growth in this customer class. Europe and Asia-Pacific / Japan delivered single-digit CER growth, while sales in the Americas were flat amid ongoing budget uncertainty and cautious spending. Full-year Academia sales rose 2% CER and represented 26% of net sales.

Building momentum for growth in 2012

QIAGEN continues to make good progress on strategic initiatives to drive growth and innovation, as demonstrated by the stronger performance in the second half of 2011 with 9% CER total sales growth over the same period in 2010. QIAGEN intends to build on this momentum and accelerate full-year growth in 2012 compared to 2011, leveraging its leadership in Sample & Assay Technologies by (1) driving platform success, especially the rollout of QIAsymphony RGQ; (2) adding content to these platforms across all customer classes; (3) broadening its geographic presence in high-growth markets; and (4) growing efficiently and effectively.

QIAsymphony RGQ is a breakthrough modular platform that has started a new era of laboratory automation and workflow consolidation. This flagship instrument is expected to be a key growth driver during the next decade and support global expansion in all customer classes, particularly Molecular Diagnostics. QIAGEN achieved its year-end 2011 goal of more than 550 QIAsymphony systems installed worldwide, and has set a new goal to reach more than 750 installed systems by the end of 2012. Customer demand is very strong for QIAsymphony given its many features, including its status as the industry's first automation system that can process both commercial assays and a broad array of laboratory-developed tests from sample to clinical result. Also in late 2011, QIAGEN introduced the novel QIAensemble Decapper, which is the first system automating the tedious process of manually handling clinical liquid sample vials.

Building on the QIAsymphony success, QIAGEN is adding high-value content for use on its automated systems, particularly novel biomarkers and companion diagnostics for use in Personalized Healthcare as well as by customers in Pharma and Academia:

Two separate U.S. regulatory submissions are under review for QIAGEN's therascreen KRAS assay as companion diagnostics for use in combination with two medicines for treatment of patients with metastatic colorectal cancer. These submissions were completed in July and August 2011, marking the first regulatory submissions by QIAGEN for companion diagnostics in the U.S. Discussions with the FDA are progressing well.
A further milestone in the Personalized Healthcare strategy was achieved in December 2011 with the regulatory approval of the therascreen EGFR mutation detection kit in Japan, which built on the country's approval of the therascreen KRAS assay in April 2011. Both tests have been shown to play an important role in guiding cancer treatment decisions. Japan is one of the largest markets for companion diagnostic tests, with a combined potential patient population for EGFR and KRAS testing estimated at approximately 100,000 per year.
At the end of 2011, QIAGEN held an 89% stake in Ipsogen S.A. (Alternext:ALIPS), a French company that is a pioneer in molecular testing for leukemia and other blood cancers. Ipsogen products are based on a rich intellectual property portfolio that includes 15 biomarkers such as JAK2, for which QIAGEN plans to develop a companion diagnostic in collaboration with Eli Lilly & Company. In July 2011 QIAGEN announced its acquisition of a majority stake in Ipsogen, and subsequently increased its holding through a public offer to acquire all remaining shares. QIAGEN intends to fully acquire Ipsogen through future public offers.
In January 2012, QIAGEN reached agreements to acquire worldwide exclusive rights to three biomarkers expected to play important roles in personalizing treatment of various cancers. A strategic co-development partnership and licensing agreement with Insight Genetics, Inc. covers a genetic test for the ALK (anaplastic lymphoma kinase) biomarker, a promising target for a novel class of lung cancer drugs. In a separate agreement between Ipsogen and Personal Genome Diagnostics Inc., QIAGEN acquired exclusive rights to testing for mutations of the IDH1 and IDH2 genes, implicated in brain cancers, acute myelogenous leukemia (AML) and certain other malignancies. QIAGEN plans to provide these biomarker assays to researchers and to develop companion diagnostics for use with new medicines.
QIAGEN also added novel content to its portfolio through the acquisition of Cellestis Limited in August 2011, gaining access to a breakthrough "pre-molecular" technology for diagnosing diseases earlier than possible with other diagnostic methods. The QuantiFERON-TB Gold (QFT) test for latent tuberculosis (TB), which is approved and recommended in national guidelines in many developed countries (including U.S., Europe and Japan), had pro forma full-year net sales of approximately $55 million in 2011 and grew at a strong double-digit CER pace. Building on that success, QIAGEN intends to submit two tests for U.S. regulatory approval in 2012 for detection of the cytomegalovirus (CMV): the QuantiFERON-CMV test and a complementary DNA-based molecular diagnostic test.

QIAGEN is expanding its geographic presence after beginning direct sales in India and Taiwan during 2011. The top seven emerging markets (Brazil, Russia, India, China, South Korea, Mexico and Turkey) represented 12% of net sales in 2011 and generated 21% CER growth compared to 2010. Key areas under consideration for expansion are in Eastern Europe, Latin America and Asia.

To grow more efficiently and effectively, QIAGEN launched a project in November 2011 to enhance productivity and free up resources for reallocation to strategic initiatives. Initial actions have focused on eliminating organizational layers, overlapping structures and duplication between global, regional and local activities. As part of this project, R&D activities will focus on high-growth areas in all customer classes. QIAGEN also plans to optimize capacity utilization at selected sites and capture savings from shared service functions. As a result of these reallocations and efficiency programs, the number of positions in QIAGEN's worldwide workforce is being reduced by approximately 8-10%, with the vast majority of actions completed by the end of January 2012. Annual pre-tax cost savings of approximately $50 million are expected to be created in 2012, with the majority to be reinvested. These actions are expected to drive improvement in the adjusted operating income margin in 2013. A pre-tax restructuring charge of approximately $75 million was taken in the fourth quarter of 2011, of which approximately 40% was cash-related. As previously announced, QIAGEN plans to take a restructuring charge in 2012 for additional restructuring measures related to this program.

2012 outlook

QIAGEN has set a goal to accelerate sales and adjusted earnings growth in 2012, building on the progress on strategic initiatives during 2011. For the full year, total net sales are expected to rise approximately 6-8% CER on a mix of organic growth and contributions from the Cellestis and Ipsogen acquisitions in 2011. Based on year-end 2011 foreign exchange rates, reported sales results are expected to be adversely affected by currency movements. Adjusted diluted earnings per share (EPS) are expected to rise to approximately $1.03 - 1.05 for full-year 2012. These expectations do not take into account any acquisitions that could be completed during the year.

Conference Call and Webcast Details

Information on QIAGEN's performance will be presented during a conference call on Wednesday, February 1, 2012, at 9:30 ET / 14:30 GMT / 15:30 CET. The corresponding presentation slides will be available for download shortly before the event at http://www.qiagen.com/goto/ConferenceCall, and a webcast will be available at this website. A replay will also be made available on this website.

Use of Adjusted Results

QIAGEN has regularly reported adjusted results, as well as results considered on a constant exchange rate basis, to give additional insight into its financial performance. These adjusted results include adjusted gross profit, adjusted operating income, adjusted net income attributable to owners of QIAGEN N.V. and adjusted diluted EPS. In addition, QIAGEN provides information on free cash flow, which it defines as net cash provided by operating activities minus purchases of property and equipment. Adjusted results are non-GAAP financial measures that the company believes should be considered in addition to the reported results prepared in accordance with generally accepted accounting principles, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Reconciliations of reported results to adjusted results are included in the tables accompanying this release.

Tables with detailed financial information can be downloaded in PDF format from: http://www.qiagen.com/about/investorrelation/aboupdf/Q4_2011_e.pdf

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2011, QIAGEN employed approximately 3,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts: Public Relations: Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email: pr@qiagen.com http://www.twitter.com/qiagen http://www.qiagen.com/about/press Investor Relations: John Gilardi VP Corporate Communications +49-2103-29-11711 +1-301-240-686-2222 Albert F. Fleury Investor Relations North America +1-301-944-7028 Email: ir@qiagen.com http://www.qiagen.com/about/investorrelation

http://ih.advfn.com/p.php?pid=nmona&article=50975675

2/1/12 Webcast of QGEN Fourth Quarter and Year End 2011 Financial Results Call Set for February 1, 2012

Press Release: QIAGEN N.V. – Tue, Jan 24, 2012 9:10 AM EST

Email
Print
Companies:
Qiagen NVQIAGEN NV
RELATED QUOTES
Symbol Price Change
QGEN 16.33 +0.64

VENLO, Netherlands, Jan. 24, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN - News) today announced the Webcast of its fourth quarter and year-end 2011 financial results call. The Webcast will take place at 9:30 a.m. ET on Wednesday, February 1, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
What: Webcast of QIAGEN's fourth quarter and year-end 2011 financial results call


When: 9:30 a.m. ET on February 1

Where: The Webcast is accessible at www.qiagen.com/goto/ConferenceCall


How: Log on to the Web at the address above
The corresponding presentation slides will be available for download in the investor relations section of QIAGEN's Web site at www.qiagen.com/goto/ConferenceCall.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
The QIAGEN N.V. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3692
Contact:
QIAGEN N.V.
ir@qiagen.com
phone +49 2103 2911709

Watch inventory? Why Qiagen May Be About to Take Off
By Seth Jayson | More Articles
January 11, 2012 |

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It’s a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.

Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Qiagen (Nasdaq: QGEN ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Qiagen doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 2.8%, and inventory increased 10.9%. Over the sequential quarterly period, the trend looks OK but not great. Revenue grew 2.4%, and inventory grew 4.4%.

Advanced inventory
I don’t stop my checkup there, because the type of inventory can matter even more than the overall quantity. There’s even one type of inventory bulge we sometimes like to see. You can check for it by examining the quarterly filings to evaluate the different kinds of inventory: raw materials, work-in-progress inventory, and finished goods. (Some companies report the first two types as a single category.)

A company ramping up for increased demand may increase raw materials and work-in-progress inventory at a faster rate when it expects robust future growth. As such, we might consider oversized growth in those categories to offer a clue to a brighter future, and a clue that most other investors will miss. We call it "positive inventory divergence.”

On the other hand, if we see a big increase in finished goods, that often means product isn’t moving as well as expected, and it’s time to hunker down with the filings and conference calls to find out why.

What’s going on with the inventory at Qiagen? I chart the details below for both quarterly and 12-month periods.





Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.


Source: S&P Capital IQ. Data is current as of latest fully-reported quarter. Dollar amounts in millions. FQ = fiscal quarter.

Let's dig into the inventory specifics. On a trailing-12-month basis, work-in-progress inventory was the fastest-growing segment, up 16.9%. On a sequential-quarter basis, finished goods inventory was the fastest-growing segment, up 7.7%. That can be a warning sign, so investors should check in with Qiagen's filings to make sure there's a good reason for packing the storeroom for this period. Although Qiagen shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.

Foolish bottom line
When you’re doing your research, remember that aggregate numbers such as inventory balances often mask situations that are more complex than they appear. Even the detailed numbers don’t give us the final word. When in doubt, listen to the conference call, or contact investor relations. What at first looks like a problem may actually signal a stock that will provide the market's best returns. And what might look hunky-dory at first glance could actually be warning you to cut your losses before the rest of the Street wises up.

I run these quick inventory checks every quarter. To stay on top of inventory and other tell-tale metrics at your favorite companies, add them to your free watchlist, and we’ll deliver our latest coverage right to your inbox.

http://www.fool.com/investing/general/2012/01/12/why-qiagen-may-be-about-to-take-off.aspx

QGEN chart: new higher high

ty was much needed, all stocks deserve a home:)

VERY Nice iBox & Due Diligence. Thanks.

ibox is updated:) enjoy

working on it as we speak:)

Way to go. B'marked. Now I know there might be some DD...

QGEN contact info: Qiagen NV
Spoorstraat 50
Venlo, 5911 KJ
Netherlands - Map
Phone: 31 77 320 8400
Fax: 31 77 320 8409
Website: http://www1.qiagen.com

QGEN Headlines:

Thursday, January 12, 2012

Qiagen Expands with New DealsZacks (Thu, Jan 12)
Why Qiagen May Be About to Take Offat Motley Fool (Thu, Jan 12)
Wednesday, January 11, 2012

[$$] Reinforcing the Supply Chainat The Wall Street Journal (Wed, Jan 11)
Tuesday, January 10, 2012

QIAGEN Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer TreatmentsPR Newswire (Tue, Jan 10)
QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion DiagnosticsPR Newswire (Tue, Jan 10)
Monday, January 9, 2012

Qiagen Expands QIAensemble PortfolioZacks (Mon, Jan 9)
QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent InfectionPR Newswire (Mon, Jan 9)
Friday, January 6, 2012

QIAGEN Launches QIAensemble Decapper Sample Preparation Automation SystemPR Newswire (Fri, Jan 6)
Wednesday, January 4, 2012

Pre-market top 5 gainerstheflyonthewall.com (Wed, Jan 4)
Pre-market top 5 gainersat theflyonthewall.com (Wed, Jan 4)
European Stocks Retreat Before Bond Auctionsat Bloomberg (Wed, Jan 4)
German Stocks Retreat From Two-Month High Before Debt Saleat Bloomberg (Wed, Jan 4)
Tuesday, January 3, 2012

Cepheid to Present at a ConferenceZacks (Tue, Jan 3)
Friday, December 16, 2011

FDA Nod for Hologic's Cervista HTAZacks (Fri, Dec 16)
Wednesday, December 14, 2011

Nasdaq 100 Re-Rank Reviewat Seeking Alpha (Wed, Dec 14)
Tuesday, December 13, 2011

Why Thermo Fisher Scientific May Be About to Take Offat Motley Fool (Tue, Dec 13)
Monday, December 12, 2011

Edwards Lifesciences, Intel, Rosetta, Vulcan: U.S. Equity Moversat Bloomberg (Mon, Dec 12)
Cepheid Stays NeutralZacks (Mon, Dec 12)
Sunday, December 11, 2011

Avago, Fossil Replace Flir, Urban Outfitters in Nasdaq-100 Indexat Bloomberg (Sun, Dec 11)
Wednesday, December 7, 2011

CBA Expects Resuscitation Of Healthcare M&A Next Yearat The Wall Street Journal (Wed, Dec 7)

chart:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70711361&txt2find=qgen

QGEN was a much needed board: QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. As of September 30, 2011 , QIAGEN employed nearly 3,800 people in over 35 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.